← Back to search
7v3p

Cryo-EM structure of the IGF1R/insulin complex

Method: ELECTRON MICROSCOPY Dmax: 170.0 Å Quality: GOOD
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Insulin-like growth factor 1 receptor

Homo sapiens

UniProt P08069

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 4 PDB declaration: tetrameric（4） Consistent with protein copy count Chain A； UniProt 1–931 Chain B； UniProt 1–931 Not recorded Insulin A chain × 1 （P01308） Insulin B chain × 1 （P01308） NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY cryo-EM buffer：pH 7.4 cryo-EM vitrification conditions：Cryogen ETHANE Resolution 3.60 Å

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7V3P Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1IGR Type 1 Insulin-like growth factor receptor (DOMAINS 1-3) Deposited 1998-09-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Monomer；Protein × 1 PDB declaration: monomeric
Chain A 31–492（462 aa） Fragment：UNP residues 31-492
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 SO4 SULFATE ION × 8 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；PROTEIN WAS CRYSTALLIZED FROM 2.0 M AMMONIUM SULFATE, 100 MM HEPES, PH 7.5
Resolution 2.60 Å R-free 0.304
1JQH IGF-1 receptor kinase domain Deposited 2001-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 979–1286（308 aa） Fragment：kinase domain
Mutation：E979G, Y980S MG MAGNESIUM ION × 1 SO4 SULFATE ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；magnesium chloride, Tris, ammonium sulphate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.10 Å R-free 0.219
1JQH IGF-1 receptor kinase domain Deposited 2001-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 979–1286（308 aa） Fragment：kinase domain
Mutation：E979G, Y980S SO4 SULFATE ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；magnesium chloride, Tris, ammonium sulphate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.10 Å R-free 0.219
1JQH IGF-1 receptor kinase domain Deposited 2001-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 979–1286（308 aa） Fragment：kinase domain
Mutation：E979G, Y980S SO4 SULFATE ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；magnesium chloride, Tris, ammonium sulphate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.10 Å R-free 0.219
1K3A Structure of the Insulin-like Growth Factor 1 Receptor Kinase Deposited 2001-10-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 988–1286（299 aa） Fragment：beta chain, kinase domain (residues 988-1286)
Non-standard monomer：Yes (specific site not provided by mmCIF) ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；PEG 8000, sodium chloride, HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.10 Å R-free 0.251
1M7N Crystal Structure of Unactivated APO Insulin-like Growth Factor-1 Receptor Kinase Domain Deposited 2002-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 974–1294（321 aa） Fragment：kinase domain (residues 974-1286)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；0.1M Tris-HCl, 0.2M MgCl2, 29% PEG 8000, 2% Ethylene glycol, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.70 Å R-free 0.294
1M7N Crystal Structure of Unactivated APO Insulin-like Growth Factor-1 Receptor Kinase Domain Deposited 2002-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 974–1294（321 aa） Fragment：kinase domain (residues 974-1286)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；0.1M Tris-HCl, 0.2M MgCl2, 29% PEG 8000, 2% Ethylene glycol, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 2.70 Å R-free 0.294
1P4O Structure of Apo unactivated IGF-1R KInase domain at 1.5A resolution. Deposited 2003-04-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 974–1294（321 aa） Fragment：kinase domain
Mutation：E1067A, E1069A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；8% PEG 8k, 0.1M LiCl, 10% ethylene glycol, 10% glycerol and 0.1M Tris-HCl buffer, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.50 Å R-free 0.236
1P4O Structure of Apo unactivated IGF-1R KInase domain at 1.5A resolution. Deposited 2003-04-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 974–1294（321 aa） Fragment：kinase domain
Mutation：E1067A, E1069A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；8% PEG 8k, 0.1M LiCl, 10% ethylene glycol, 10% glycerol and 0.1M Tris-HCl buffer, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.50 Å R-free 0.236
1P4O Structure of Apo unactivated IGF-1R KInase domain at 1.5A resolution. Deposited 2003-04-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 974–1294（321 aa） Fragment：kinase domain
Chain B 974–1294（321 aa） Fragment：kinase domain
Mutation：E1067A, E1069A Mutation：E1067A, E1069A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；8% PEG 8k, 0.1M LiCl, 10% ethylene glycol, 10% glycerol and 0.1M Tris-HCl buffer, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.50 Å R-free 0.236
2OJ9 Structure of IGF-1R kinase domain complexed with a benzimidazole inhibitor Deposited 2007-01-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 982–1286（305 aa） Fragment：KINASE DOMAIN, RESIDUES 982-1286
Not recorded BMI 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions 277 K；VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.00 Å R-free 0.276
2ZM3 Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor Deposited 2008-04-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Non-standard monomer：Yes (specific site not provided by mmCIF) 575 (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.1M Tris-HCl, pH8, 2M NaCl, 13-16% PEG6K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.50 Å R-free 0.257
2ZM3 Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor Deposited 2008-04-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Non-standard monomer：Yes (specific site not provided by mmCIF) 575 (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.1M Tris-HCl, pH8, 2M NaCl, 13-16% PEG6K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.50 Å R-free 0.257
2ZM3 Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor Deposited 2008-04-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Non-standard monomer：Yes (specific site not provided by mmCIF) 575 (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.1M Tris-HCl, pH8, 2M NaCl, 13-16% PEG6K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.50 Å R-free 0.257
2ZM3 Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor Deposited 2008-04-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Non-standard monomer：Yes (specific site not provided by mmCIF) 575 (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.1M Tris-HCl, pH8, 2M NaCl, 13-16% PEG6K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.50 Å R-free 0.257
2ZM3 Complex Structure of Insulin-like Growth Factor Receptor and Isoquinolinedione Inhibitor Deposited 2008-04-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric
Chain A 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Chain B 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Chain C 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Chain D 981–1286（306 aa） Fragment：UNP residues 981-1286, IGF-1R Kinase domain
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) 575 (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.1M Tris-HCl, pH8, 2M NaCl, 13-16% PEG6K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.50 Å R-free 0.257
3D94 Crystal structure of the insulin-like growth factor-1 receptor kinase in complex with PQIP Deposited 2008-05-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 986–1286（301 aa） Fragment：Protein Kinase domain
Non-standard monomer：Yes (specific site not provided by mmCIF) CA CALCIUM ION × 2 D94 3-[cis-3-(4-methylpiperazin-1-yl)cyclobutyl]-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-amine × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；293 K；12% PEG8000, 0.1 M imidazole, pH 7.5 and 0.2 M calcium acetate, VAPOR DIFFUSION, temperature 293K
Resolution 2.30 Å R-free 0.236
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 10 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain J 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 11 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain K 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 12 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain M 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 13 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain L 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 14 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain R 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 15 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain S 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 16 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain T 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 17 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric
Chain C 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Chain D 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Chain G 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Chain H 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Chain K 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Chain L 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Chain M 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Chain R 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain E 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain F 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain G 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain H 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3F5P Complex Structure of Insulin-like Growth Factor Receptor and 3-Cyanoquinoline Inhibitor Deposited 2008-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 9 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain I 981–1286（306 aa） Fragment：IGF-1R Kinase Domain, UNP residues 981-1286
Non-standard monomer：Yes (specific site not provided by mmCIF) 741 4-[[3-chloro-4-(1-methylimidazol-2-yl)sulfanyl-phenyl]amino]-7-[3-(2-hydroxyethyl-methyl-amino)propoxy]-6-methoxy-quinoline-3-carbonitrile × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；277 K；0.1M Tris-HCl, pH8.5, 2M NaCl, 14% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.258
3I81 Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with BMS-754807 [1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoro-3-pyridinyl)-2-methyl-L-prolinamide] Deposited 2009-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 982–1286（305 aa） Fragment：Protein kinase domain, UNP residues 982-1286
Not recorded EBI 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-proli namide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.08 Å R-free 0.265
3LVP Crystal structure of bisphosphorylated IGF1-R Kinase domain (2P) in complex with a bis-azaindole inhibitor Deposited 2010-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 951–1286（336 aa） Fragment：kinase domain (2P)
Not recorded PDR 3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxy-1-methyl-1H-pyrrolo[3,2-b]pyridine × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；2.4M Ammonium Sulfate, 100mM Hepes, 5% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
Resolution 3.00 Å R-free 0.279
3LVP Crystal structure of bisphosphorylated IGF1-R Kinase domain (2P) in complex with a bis-azaindole inhibitor Deposited 2010-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 951–1286（336 aa） Fragment：kinase domain (2P)
Not recorded PDR 3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxy-1-methyl-1H-pyrrolo[3,2-b]pyridine × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；2.4M Ammonium Sulfate, 100mM Hepes, 5% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
Resolution 3.00 Å R-free 0.279
3LVP Crystal structure of bisphosphorylated IGF1-R Kinase domain (2P) in complex with a bis-azaindole inhibitor Deposited 2010-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 951–1286（336 aa） Fragment：kinase domain (2P)
Not recorded PDR 3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxy-1-methyl-1H-pyrrolo[3,2-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；2.4M Ammonium Sulfate, 100mM Hepes, 5% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
Resolution 3.00 Å R-free 0.279
3LVP Crystal structure of bisphosphorylated IGF1-R Kinase domain (2P) in complex with a bis-azaindole inhibitor Deposited 2010-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 951–1286（336 aa） Fragment：kinase domain (2P)
Not recorded PDR 3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)-5,6-dimethoxy-1-methyl-1H-pyrrolo[3,2-b]pyridine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；2.4M Ammonium Sulfate, 100mM Hepes, 5% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
Resolution 3.00 Å R-free 0.279
3LW0 IGF-1RK in complex with ligand MSC1609119A-1 Deposited 2010-02-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 983–1286（304 aa） Fragment：PROTEIN KINASE, UNP residues 983-1286
Mutation：E1097A, E1099A CCX 3-cyano-N-{1-[4-(5-cyano-1H-indol-3-yl)butyl]piperidin-4-yl}-1H-indole-7-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 0；pH 0.0
Resolution 1.79 Å R-free 0.185
3LW0 IGF-1RK in complex with ligand MSC1609119A-1 Deposited 2010-02-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 983–1286（304 aa） Fragment：PROTEIN KINASE, UNP residues 983-1286
Mutation：E1097A, E1099A CCX 3-cyano-N-{1-[4-(5-cyano-1H-indol-3-yl)butyl]piperidin-4-yl}-1H-indole-7-carboxamide × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 0；pH 0.0
Resolution 1.79 Å R-free 0.185
3LW0 IGF-1RK in complex with ligand MSC1609119A-1 Deposited 2010-02-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 983–1286（304 aa） Fragment：PROTEIN KINASE, UNP residues 983-1286
Mutation：E1097A, E1099A CCX 3-cyano-N-{1-[4-(5-cyano-1H-indol-3-yl)butyl]piperidin-4-yl}-1H-indole-7-carboxamide × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 0；pH 0.0
Resolution 1.79 Å R-free 0.185
3LW0 IGF-1RK in complex with ligand MSC1609119A-1 Deposited 2010-02-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 983–1286（304 aa） Fragment：PROTEIN KINASE, UNP residues 983-1286
Mutation：E1097A, E1099A CCX 3-cyano-N-{1-[4-(5-cyano-1H-indol-3-yl)butyl]piperidin-4-yl}-1H-indole-7-carboxamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 0；pH 0.0
Resolution 1.79 Å R-free 0.185
3NW5 Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (11B) Deposited 2010-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 982–1286（305 aa） Fragment：KINASE DOMAIN (RESIDUES 982-1286)
Not recorded LGX N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-{(2R)-1-[(6-fluoropyridin-3-yl)carbonyl]pyrrolidin-2-yl}pyrrolo[2,1-f][1,2,4]triazin-4-amine × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.14 Å R-free 0.254
3NW6 Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (11A) Deposited 2010-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 982–1286（305 aa） Fragment：KINASE DOMAIN (RESIDUES 982-1286)
Not recorded LGW N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-{(2S)-1-[(6-fluoropyridin-3-yl)carbonyl]pyrrolidin-2-yl}pyrrolo[2,1-f][1,2,4]triazin-4-amine × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.20 Å R-free 0.253
3NW7 Crystal structure of insulin-like growth factor 1 receptor (IGF-1R-WT) complex with a carbon-linked proline isostere inhibitor (34) Deposited 2010-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 982–1286（305 aa） Fragment：KINASE DOMAIN (RESIDUES 982-1286)
Not recorded LGV N-({4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}methyl)-6-fluoropyridine-3-carboxamide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.11 Å R-free 0.226
3O23 Human unphosphorylated IGF1-R Kinase domain in complex with an hydantoin inhibitor Deposited 2010-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 982–1286（305 aa） Fragment：Kinase domain
Mutation：Y987F MQY (5S)-5-methyl-1-(quinolin-4-ylmethyl)-3-{4-[(trifluoromethyl)sulfonyl]phenyl}imidazolidine-2,4-dione × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；40% PEG400, 50mM Mes, 100mM NaCl, 10% glycerol, 5mM DTT, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 2.10 Å R-free 0.278
3QQU Cocrystal structure of unphosphorylated igf with pyrimidine 8 Deposited 2011-02-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 988–1286（299 aa） Fragment：UNP residues 988-1286
Not recorded 01P N~2~-[3-methoxy-4-(morpholin-4-yl)phenyl]-N~4~-(quinolin-3-yl)pyrimidine-2,4-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M Mg Acetate, 15%-17.5% PEG8K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.302
3QQU Cocrystal structure of unphosphorylated igf with pyrimidine 8 Deposited 2011-02-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 988–1286（299 aa） Fragment：UNP residues 988-1286
Not recorded 01P N~2~-[3-methoxy-4-(morpholin-4-yl)phenyl]-N~4~-(quinolin-3-yl)pyrimidine-2,4-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M Mg Acetate, 15%-17.5% PEG8K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.302
3QQU Cocrystal structure of unphosphorylated igf with pyrimidine 8 Deposited 2011-02-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 988–1286（299 aa） Fragment：UNP residues 988-1286
Not recorded 01P N~2~-[3-methoxy-4-(morpholin-4-yl)phenyl]-N~4~-(quinolin-3-yl)pyrimidine-2,4-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M Mg Acetate, 15%-17.5% PEG8K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.302
3QQU Cocrystal structure of unphosphorylated igf with pyrimidine 8 Deposited 2011-02-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 988–1286（299 aa） Fragment：UNP residues 988-1286
Not recorded 01P N~2~-[3-methoxy-4-(morpholin-4-yl)phenyl]-N~4~-(quinolin-3-yl)pyrimidine-2,4-diamine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；0.2M Mg Acetate, 15%-17.5% PEG8K, VAPOR DIFFUSION, HANGING DROP, temperature 277K
Resolution 2.90 Å R-free 0.302
4D2R Human IGF in complex with a Dyrk1B inhibitor Deposited 2014-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 985–1286（302 aa） Fragment：KINASE DOMAIN, RESIDUES 985-1286
Not recorded CL CHLORIDE ION × 1 DYK N-{2-methoxy-4-[(1-methylpiperidin-4-yl)oxy]phenyl}-4-(1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；20% PEF3350, 0.2M MGCL2, 0.1M PCTP PH 7.5
Resolution 2.10 Å R-free 0.221
5FXQ IGFR-1R complex with a pyrimidine inhibitor. Deposited 2016-03-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 980–1286（307 aa） Fragment：KINASE, UNP RESIDUES 980-1286
Not recorded GD5 5-chloranyl-4-imidazo[1,2-a]pyridin-3-yl-N-(5-methyl-1-piperidin-4-yl-pyrazol-4-yl)pyrimidin-2-amine × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å R-free 0.275
5FXR IGFR-1R complex with a pyrimidine inhibitor. Deposited 2016-03-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 980–1286（307 aa） Fragment：KINASE, UNP RESIDUES 980-1286
Not recorded 8LN 5-chloranyl-4-imidazo[1,2-a]pyridin-3-yl-N-(3-methyl-1-piperidin-4-yl-pyrazol-4-yl)pyrimidin-2-amine × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.40 Å R-free 0.294
5FXS IGFR-1R complex with a pyrimidine inhibitor. Deposited 2016-03-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 980–1286（307 aa） Fragment：KINASE, UNP RESIDUES 980-1286
Not recorded ACT ACETATE ION × 3 OZN 2-[4-[4-[[(6Z)-5-chloranyl-6-pyrazolo[1,5-a]pyridin-3-ylidene-1H-pyrimidin-2-yl]amino]-3,5-dimethyl-pyrazol-1-yl]piperidin-1-yl]-N,N-dimethyl-ethanamide × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å R-free 0.214
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain E 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain F 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain G 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5HZN Structure of NVP-AEW541 in complex with IGF-1R kinase Deposited 2016-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain H 983–1286（304 aa）
Not recorded 66A 7-[cis-3-(azetidin-1-ylmethyl)cyclobutyl]-5-[3-(benzyloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.25；293 K；25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL
Resolution 2.20 Å R-free 0.218
5U8Q Structure of the ectodomain of the human Type 1 insulin-like growth factor receptor in complex with IGF-I Deposited 2016-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric
Chain A 31–935（905 aa）
Mutation：residues 718-741 are replaced with the sequence AGNN SO4 SULFATE ION × 4 MLT D-MALATE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.2 M ammonium sulfate, 0.1 M imidazole-malate pH 7.0. IGF-1 was included by soaking directly into the mother crystal. For full details see the primary citation.
Resolution 3.27 Å R-free 0.303
5U8R Structure of the ectodomain of the human Type 1 insulin-like growth factor receptor Deposited 2016-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 31–935（905 aa）
Mutation：residues 718-741 are replaced with the sequence AGNN SO4 SULFATE ION × 2 MLT D-MALATE × 4 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 IMD IMIDAZOLE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.2 M ammonium sulfate, 0.1 M imidazole-malate pH 7.0
Resolution 3.00 Å R-free 0.285
6JK8 Cryo-EM structure of the full-length human IGF-1R in complex with insulin Deposited 2019-02-27 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 1–1367（1367 aa）
Chain B 1–1367（1367 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4；PBS with detergent
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 5.00 Å
6VWG Head region of the open conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II. Deposited 2020-02-19 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 31–935（905 aa）
Chain B 31–935（905 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.21 Å
6VWH Leg region of the open conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II. Deposited 2020-02-19 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–935（905 aa）
Chain B 31–935（905 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.26 Å
6VWI Head region of the closed conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II. Deposited 2020-02-19 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 31–935（905 aa）
Chain B 31–935（905 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.70 Å
6VWJ Leg region of the closed conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor II Deposited 2020-02-19 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–935（905 aa）
Chain B 31–935（905 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.21 Å
7PH8 Structure of Insulin-like growth factor 1 receptor's transmembrane domain Deposited 2021-08-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 932–962（31 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.7；313 K；Ionic strength (raw mmCIF value) 0.1；Pressure AMBIENT
NMR sample composition 0.5 mM [U-100% 13C; U-100% 15N] IGF1Rtm, 100 mM [U-99% 2H] DPC, 0.3 mM sodium azide, 30 mM KH2PO4, 20 mM K2HPO4, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
7S0Q Head region of a complex of IGF-I with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor Deposited 2021-08-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 31–935（905 aa）
Not recorded BMA beta-D-mannopyranose × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 ELECTRON MICROSCOPY
cryo-EM buffer pH 8；20mM Tris pH 8.0 160mM NaCl
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.70 Å
7S8V Leg region of a complex of IGF-I with the ectodomain of a hybrid insulin receptor / type 1 insulin-like growth factor receptor Deposited 2021-09-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric
Chain A 31–935（905 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.73 Å
7U23 Single-chain LCDV-1 viral insulin-like peptide bound to IGF-1R ectodomain, leucine-zippered form Deposited 2022-02-22 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain E 31–935（905 aa）
Chain F 31–935（905 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.60 Å
7XGD Cryo-EM structure of Apo-IGF1R map 1 Deposited 2022-04-04 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–927（897 aa）
Chain B 31–927（897 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen OTHER
Resolution 4.00 Å
7XLC conformation II of apo-IGF1R states Deposited 2022-04-21 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–927（897 aa）
Chain B 31–927（897 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen OTHER
Resolution 5.00 Å
7YRR Cryo-EM structure of IGF1R with two IGF1 complex Deposited 2022-08-10 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 31–927（897 aa）
Chain B 31–927（897 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen OTHER
Resolution 4.30 Å
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain AAA 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain BBB 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain CCC 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain DDD 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain EEE 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain FFF 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain GGG 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYI Human IGF1R with inhibitor 6 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain HHH 974–1286（313 aa）
Not recorded IER 3-[8-azanyl-1-(4-ethoxy-8-fluoranyl-2-phenyl-quinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutan-1-ol × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M Bis-Tris, 0.3 M MgCl2, 20% PEG 3350
Resolution 3.06 Å R-free 0.235
8PYJ Human IGF1R with inhibitor 8 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain AAA 974–1286（313 aa）
Not recorded IEA 5,5-dimethyl-1-(quinolin-4-ylmethyl)-3-[4-(trifluoromethylsulfonyl)phenyl]imidazolidine-2,4-dione × 1 NI NICKEL (II) ION × 1 CD CADMIUM ION × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M HEPES pH 7.5-8.5, 9-12 % PEG3350, 5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2, and 5 mM NiCl2
Resolution 2.70 Å R-free 0.302
8PYK Human IGF1R with inhibitor 47 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain AAA 974–1286（313 aa）
Not recorded IC2 5,5-dimethyl-1-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione × 1 NI NICKEL (II) ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M HEPES pH 7.5-8.5, 9-12 % PEG3350, 5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2, and 5 mM NiCl2
Resolution 2.23 Å R-free 0.253
8PYL Human IGF1R with inhibitor 53 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain AAA 974–1286（313 aa）
Not recorded IE0 (5S)-5-methyl-1-(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione × 1 NI NICKEL (II) ION × 1 CD CADMIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M HEPES pH 7.5-8.5, 9-12 % PEG3350, 5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2, and 5 mM NiCl2
Resolution 2.93 Å R-free 0.249
8PYM Human IGF1R with inhibitor 54 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain AAA 974–1286（313 aa）
Not recorded IED 5,5-dimethyl-1-(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione × 1 NI NICKEL (II) ION × 1 CD CADMIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M HEPES pH 7.5-8.5, 9-12 % PEG3350, 5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2, and 5 mM NiCl2
Resolution 2.65 Å R-free 0.309
8PYN Human IGF1R with inhibitor 56 Deposited 2023-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain AAA 974–1286（313 aa）
Not recorded ICV 5,5-dimethyl-1-(1H-pyrrolo[2,3-b]pyridin-4-ylmethyl)-3-[4-(trifluoromethylsulfonyl)phenyl]imidazolidine-2,4-dione × 1 CD CADMIUM ION × 1 NI NICKEL (II) ION × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.1 M HEPES pH 7.5-8.5, 9-12 % PEG3350, 5 mM CoCl2, 5 mM CdCl2, 5 mM MgCl2, and 5 mM NiCl2
Resolution 1.71 Å R-free 0.209
8TAN CryoEM structure of MFRV-VILP bound to IGF1Rzip Deposited 2023-06-27 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 31–935（905 aa）
Chain B 31–935（905 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 11 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.05 Å
9NCO IN-ML-15 bound to IGF1Rzip Deposited 2025-02-16 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 31–926（896 aa）
Chain B 31–926（896 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å

44 other PDB entries and 92 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name IGF1R_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 1–931； UniProt 1–931 Author chain B； PDBConstruct 1–931； UniProt 1–931

Insulin A chain

Homo sapiens

UniProt P01308

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein heterocomplex Heteromer Protein × 4 PDB declaration: tetrameric（4） Consistent with protein copy count Chain E； UniProt 90–110 Chain F； UniProt 25–54 Not recorded Insulin-like growth factor 1 receptor × 2 （P08069） NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY cryo-EM buffer：pH 7.4 cryo-EM vitrification conditions：Cryogen ETHANE Resolution 3.60 Å

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7V3P Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1A7F INSULIN MUTANT B16 GLU, B24 GLY, DES-B30, NMR, 20 STRUCTURES Deposited 1998-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：Y16E, F24G, DEL(T30) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 8；305 K
NMR sample composition WATER
Resolution not provided
1AI0 R6 HUMAN INSULIN HEXAMER (NON-SYMMETRIC), NMR, 10 STRUCTURES Deposited 1997-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded ZN ZINC ION × 2 IPH PHENOL × 6 SOLUTION NMR
NMR measurement conditions pH 8；310 K
Resolution not provided
1AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 10 STRUCTURES Deposited 1997-04-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded ZN ZINC ION × 2 IPH PHENOL × 6 SOLUTION NMR
NMR measurement conditions pH 8；310 K
Resolution not provided
1B9E HUMAN INSULIN MUTANT SERB9GLU Deposited 1998-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：S9E Mutation：S9E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 3.5；HANGING DROP, 0.1M AMMONIA CITRATE, 0.12% CHROMIUM DICHLORIDE (W/V), 10% ACETONE (V/V), 4% DIMETHYL FORMAMIDE (V/V), PH 3.8, pH 3.5, VAPOR DIFFUSION, HANGING DROP
Resolution 2.50 Å R-free 0.264
1B9E HUMAN INSULIN MUTANT SERB9GLU Deposited 1998-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：S9E Mutation：S9E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 3.5；HANGING DROP, 0.1M AMMONIA CITRATE, 0.12% CHROMIUM DICHLORIDE (W/V), 10% ACETONE (V/V), 4% DIMETHYL FORMAMIDE (V/V), PH 3.8, pH 3.5, VAPOR DIFFUSION, HANGING DROP
Resolution 2.50 Å R-free 0.264
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 10 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 11 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 12 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain B 1–30（30 aa）
Chain C 31–51（21 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 13 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain B 1–30（30 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 31–51（21 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 1 HBD 4-HYDROXYBENZAMIDE × 2 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Chain C 31–51（21 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Chain C 31–51（21 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Chain C 31–51（21 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Chain C 31–51（21 aa）
Not recorded ZN ZINC ION × 3 HBD 4-HYDROXYBENZAMIDE × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 31–51（21 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 3 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 9 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain B 1–30（30 aa）
Chain C 31–51（21 aa）
Chain D 1–30（30 aa）
Not recorded ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
Resolution 1.40 Å
1EFE AN ACTIVE MINI-PROINSULIN, M2PI Deposited 2000-02-08 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 25–54（30 aa）
Chain A 90–110（21 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 2.3；303 K；Pressure ambient
NMR sample composition 2mM M2PI U-15N; 20% acetic acid; 70% H2O, 10% D2O | 20% acetic acid, 70% H2O, 10% D2O
NMR sample composition 2mM M2PI; 20% acetic acid; 70% H2O, 10% D2O | 20% acetic acid, 70% H2O, 10%
Resolution not provided
1EV3 Structure of the rhombohedral form of the M-cresol/insulin R6 hexamer Deposited 2000-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：RESIDUES 87-107
Chain B 25–54（30 aa） Fragment：RESIDUES 25-54
Chain C 90–110（21 aa） Fragment：RESIDUES 87-107
Chain D 25–54（30 aa） Fragment：RESIDUES 25-54
Not recorded CRS M-CRESOL × 9 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 8.5；298 K；30 mg insulin, 3.0 ml of 0.02 M HCl, 0.3 ml of 0.15 M Zinc Acetate, 1.5 ml of 0.2 M Sodium Citrate, 1.2 ml of 2.5% m-cresol in acetone, 0.36 gm sodium chloride, pH 8.5, SLOW COOLING, temperature 298K
Resolution 1.78 Å R-free 0.266
1EV6 Structure of the monoclinic form of the M-cresol/insulin R6 hexamer Deposited 2000-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：RESIDUES 87-107
Chain B 25–54（30 aa） Fragment：RESIDUES 25-54
Chain C 90–110（21 aa） Fragment：RESIDUES 87-107
Chain D 25–54（30 aa） Fragment：RESIDUES 25-54
Chain E 90–110（21 aa） Fragment：RESIDUES 87-107
Chain F 25–54（30 aa） Fragment：RESIDUES 25-54
Chain G 90–110（21 aa） Fragment：RESIDUES 87-107
Chain H 25–54（30 aa） Fragment：RESIDUES 25-54
Chain I 90–110（21 aa） Fragment：RESIDUES 87-107
Chain J 25–54（30 aa） Fragment：RESIDUES 25-54
Chain K 90–110（21 aa） Fragment：RESIDUES 87-107
Chain L 25–54（30 aa） Fragment：RESIDUES 25-54
Not recorded CRS M-CRESOL × 7 ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.5；298 K；30 mg insulin, 3.0 ml 0.02 M HCl, 0.3 ml 0.15 M Zinc Acetate, 1.5 ml 0.2 M Sodium Citrate, 1.2 ml 5% m-Cresol in ethanol, pH 6.5, SLOW COOLING, temperature 298.0K
Resolution 1.90 Å R-free 0.235
1EVR The structure of the resorcinol/insulin R6 hexamer Deposited 2000-04-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：RESIDUES 87-107
Chain B 25–54（30 aa） Fragment：RESIDUES 25-54
Chain C 90–110（21 aa） Fragment：RESIDUES 87-107
Chain D 25–54（30 aa） Fragment：RESIDUES 25-54
Chain E 90–110（21 aa） Fragment：RESIDUES 87-107
Chain F 25–54（30 aa） Fragment：RESIDUES 25-54
Chain G 90–110（21 aa） Fragment：RESIDUES 87-107
Chain H 25–54（30 aa） Fragment：RESIDUES 25-54
Chain I 90–110（21 aa） Fragment：RESIDUES 87-107
Chain J 25–54（30 aa） Fragment：RESIDUES 25-54
Chain K 90–110（21 aa） Fragment：RESIDUES 87-107
Chain L 25–54（30 aa） Fragment：RESIDUES 25-54
Not recorded RCO RESORCINOL × 8 ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.7；298 K；30 mg insulin, 3.0 ml 0.02 M HCl, 0.3 ml 0.15 M Zinc Acetate, 1.5 ml 0.2 M Sodium Citrate, 1.2 ml 5% Resorcinol in water, 0.36 gm NaCl, pH 6.7, SLOW COOLING, temperature 298.0K
Resolution 1.90 Å R-free 0.218
1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric
Chain A 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain B 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain C 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain D 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain E 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain F 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain G 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain H 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Not recorded ZN ZINC ION × 4 CL CHLORIDE ION × 4 NA SODIUM ION × 2 POWDER DIFFRACTION mmCIF provides none of the parsed conditions Resolution not provided
1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain F 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain G 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain H 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 POWDER DIFFRACTION mmCIF provides none of the parsed conditions Resolution not provided
1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain B 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain C 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain D 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 POWDER DIFFRACTION mmCIF provides none of the parsed conditions Resolution not provided
1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain C 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain D 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain E 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain F 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 POWDER DIFFRACTION mmCIF provides none of the parsed conditions Resolution not provided
1FUB FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain B 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain C 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain D 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 POWDER DIFFRACTION
X-ray crystallization conditions grinding；300 K；grinding, temperature 300K
Resolution not provided
1FUB FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain B 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Chain C 90–110（21 aa） Fragment：A CHAIN OF T3R3 VARIANT
Chain D 25–54（30 aa） Fragment：B CHAIN OF T3R3 VARIANT
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 POWDER DIFFRACTION
X-ray crystallization conditions grinding；300 K；grinding, temperature 300K
Resolution not provided
1G7A 1.2 A structure of T3R3 human insulin at 100 K Deposited 2000-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 87–107（21 aa） Fragment：A-CHAIN
Chain B 25–54（30 aa） Fragment：B-CHAIN
Chain C 87–107（21 aa） Fragment：A-CHAIN
Chain D 25–54（30 aa） Fragment：B-CHAIN
Not recorded ZN ZINC ION × 15 CL CHLORIDE ION × 12 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate, 17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
Resolution 1.20 Å R-free 0.193
1G7A 1.2 A structure of T3R3 human insulin at 100 K Deposited 2000-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 87–107（21 aa） Fragment：A-CHAIN
Chain F 25–54（30 aa） Fragment：B-CHAIN
Chain G 87–107（21 aa） Fragment：A-CHAIN
Chain H 25–54（30 aa） Fragment：B-CHAIN
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 9 ACN ACETONE × 6 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate, 17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
Resolution 1.20 Å R-free 0.193
1G7B 1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K Deposited 2000-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 87–107（21 aa） Fragment：A-CHAIN
Chain B 25–54（30 aa） Fragment：B-CHAIN
Chain C 87–107（21 aa） Fragment：A-CHAIN
Chain D 25–54（30 aa） Fragment：B-CHAIN
Not recorded ZN ZINC ION × 15 CL CHLORIDE ION × 12 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate, 17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
Resolution 1.30 Å R-free 0.204
1G7B 1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K Deposited 2000-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 87–107（21 aa） Fragment：A-CHAIN
Chain F 25–54（30 aa） Fragment：B-CHAIN
Chain G 87–107（21 aa） Fragment：A-CHAIN
Chain H 25–54（30 aa） Fragment：B-CHAIN
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 9 GOL GLYCEROL × 3 ACN ACETONE × 3 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate, 17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
Resolution 1.30 Å R-free 0.204
1GUJ Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation. Deposited 2002-01-28 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 2.1；HANGING DROP VAPOUR DIFFUSION METHOD PROTEIN SOL: 5 MG/ML HUMAN INSULIN IN SULPHURIC ACID PH 2.1 RESERVOIR SOL: SULPHURIC ACID PH 2.1,0.025 M SODIUM SULPHATE
Resolution 1.62 Å R-free 0.207
1GUJ Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation. Deposited 2002-01-28 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 2.1；HANGING DROP VAPOUR DIFFUSION METHOD PROTEIN SOL: 5 MG/ML HUMAN INSULIN IN SULPHURIC ACID PH 2.1 RESERVOIR SOL: SULPHURIC ACID PH 2.1,0.025 M SODIUM SULPHATE
Resolution 1.62 Å R-free 0.207
1HIQ PARADOXICAL STRUCTURE AND FUNCTION IN A MUTANT HUMAN INSULIN ASSOCIATED WITH DIABETES MELLITUS Deposited 1993-03-05 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：F24S No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1HIS Structure and dynamics of des-pentapeptide-insulin in solution: the molten-globule hypothesis. Deposited 1992-02-28 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–49（25 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1HIT Receptor binding redefined by a structural switch in a mutant Human Insulin Deposited 1992-02-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：F24G No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1HLS NMR STRUCTURE OF THE HUMAN INSULIN-HIS(B16) Deposited 1995-06-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：TYR 16 B HIS Mutation：TYR 16 B HIS No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1HTV CRYSTAL STRUCTURE OF DESTRIPEPTIDE (B28-B30) INSULIN Deposited 2001-01-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain B 25–51（27 aa） Fragment：INSULIN B CHAIN
Chain C 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain D 25–51（27 aa） Fragment：INSULIN B CHAIN
Chain E 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain F 25–51（27 aa） Fragment：INSULIN B CHAIN
Chain G 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain H 25–51（27 aa） Fragment：INSULIN B CHAIN
Chain I 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain J 25–51（27 aa） Fragment：INSULIN B CHAIN
Chain K 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain L 25–51（27 aa） Fragment：INSULIN B CHAIN
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；298 K；sodium citrate, dimethylformamide, zinc acetate, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
Resolution 1.90 Å R-free 0.240
1HUI INSULIN MUTANT (B1, B10, B16, B27)GLU, DES-B30, NMR, 25 STRUCTURES Deposited 1996-03-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 26–53（28 aa）
Mutation：CHAIN B, F1E, H10E, Y16E, T27E, DEL(T30) Mutation：CHAIN B, F1E, H10E, Y16E, T27E, DEL(T30) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；307 K
Resolution not provided
1IOG INSULIN MUTANT A3 GLY,(B1, B10, B16, B27)GLU, DES-B30, NMR, 19 STRUCTURES Deposited 1998-08-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 26–53（28 aa）
Mutation：V3G Mutation：F1E, H10E, Y16E, T27E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；307 K
Resolution not provided
1IOH INSULIN MUTANT A8 HIS,(B1, B10, B16, B27)GLU, DES-B30, NMR, 26 STRUCTURES Deposited 1998-08-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：90-110
Chain B 26–53（28 aa） Fragment：25-53
Mutation：T8H Mutation：F1E, H10E, Y16E, T27E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；307 K
Resolution not provided
1J73 Crystal structure of an unstable insulin analog with native activity. Deposited 2001-05-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：T8(DAB) Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：T8(DAB) Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；298 K；Tris, phonel, acetone, sodium citrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.273
1JCA Non-standard Design of Unstable Insulin Analogues with Enhanced Activity Deposited 2001-06-08 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：T8K ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；Tris, sodium citrate, acetone, phenol, pH 7.0, VAPOR DIFFUSION, HANGING DROP
Resolution 2.50 Å R-free 0.241
1JCA Non-standard Design of Unstable Insulin Analogues with Enhanced Activity Deposited 2001-06-08 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：T8K ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；Tris, sodium citrate, acetone, phenol, pH 7.0, VAPOR DIFFUSION, HANGING DROP
Resolution 2.50 Å R-free 0.241
1JCA Non-standard Design of Unstable Insulin Analogues with Enhanced Activity Deposited 2001-06-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：T8K Mutation：T8K ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；Tris, sodium citrate, acetone, phenol, pH 7.0, VAPOR DIFFUSION, HANGING DROP
Resolution 2.50 Å R-free 0.241
1JCO Solution structure of the monomeric [Thr(B27)->Pro,Pro(B28)->Thr] insulin mutant (PT insulin) Deposited 2001-06-11 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：T27P, P28T No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 3.13；298 K；Pressure 1
NMR sample composition 2.8 mM PT-insulin; 10%D2O; 90%H2O | 10% D2O, 90% H2O
NMR sample composition 2.8 mM PT-insulin; 100% D2O | 100% D2O
NMR sample composition 2.8 mM PT-insulin; 35% Trifluoroethanol; 5% D2O; 60% H2O | 35% Trifluoroethanol; 5% D2O; 60% H2O
NMR sample composition 2.8 mM PT-insulin; 35% Trifluoroethanol; 65% D2O; | 35% Trifluoroethanol; 65% D2O;
Resolution not provided
1K3M NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALA, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2001-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：INSULIN A CHAIN (residues 90-110)
Chain B 25–54（30 aa） Fragment：INSULIN B CHAIN (residues 25-54)
Mutation：I2A Mutation：H10D, P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Pressure ambient
NMR measurement conditions pH 7.6；303 K；Pressure ambient
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 1.2 mM AlaA2-DKP-Insulin; 100% D2O; | 100% D2O
NMR sample composition 1.2 mM AlaA2-DKP-Insulin; 90% H2O, 10% D2O; | 90% H2O/10% D2O
NMR sample composition 1.2 mM AlaA2-DKP-Insulin; 20% Deuteroacetic Acid, 80% D2O; | 20% Deuteroacetic Acid, 80% D2O;
Resolution not provided
1KMF NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALLO-ILE, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2001-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 87–107（21 aa）
Chain B 25–54（30 aa）
Mutation：I2(IIL) Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：H10D, P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Pressure ambient
NMR measurement conditions pH 7.6；305 K；Pressure ambient
NMR sample composition 1.2 mM Allo-Ile-A2-DKP-insulin; 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition 1.2 mM Allo-Ile-A2-DKP-insulin; 100% D2O | 100% D2O
Resolution not provided
1LKQ NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES Deposited 2002-04-25 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：I2G,V3G Mutation：H10D,P28K,K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Pressure AMBIENT
NMR sample composition 1.0 MM GLYA2,A3-DKP- INSULIN; 90% H2O/10% D2O;
Resolution not provided
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 1 IPH PHENOL × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 2 IPH PHENOL × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 2 IPH PHENOL × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 3 IPH PHENOL × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P ZN ZINC ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1MHI THREE-DIMENSIONAL SOLUTION STRUCTURE OF AN INSULIN DIMER. A STUDY OF THE B9(ASP) MUTANT OF HUMAN INSULIN USING NUCLEAR MAGNETIC RESONANCE DISTANCE GEOMETRY AND RESTRAINED MOLECULAR DYNAMICS Deposited 1994-11-30 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：S(B 9)D Mutation：S(B 9)D No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1MHJ SOLUTION STRUCTURE OF THE SUPERACTIVE MONOMERIC DES-[PHE(B25)] HUMAN INSULIN MUTANT. ELUCIDATION OF THE STRUCTURAL BASIS FOR THE MONOMERIZATION OF THE DES-[PHE(B25)] INSULIN AND THE DIMERIZATION OF NATIVE INSULIN Deposited 1994-11-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–48（24 aa）
Mutation：DES-[PHE(B 25)] Mutation：DES-[PHE(B 25)] No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1MSO T6 Human Insulin at 1.0 A Resolution Deposited 2002-09-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.3；298 K；0.001 M HCl, 0.007 M Zinc Acetate, 0.05 M Sodium Citrate, 17% acetone, pH 6.3, SLOW COOLING at 298K, temperature 298.0K
Resolution 1.00 Å R-free 0.201
1OS3 Dehydrated T6 human insulin at 100 K Deposited 2003-03-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：A-chain
Chain B 25–54（30 aa） Fragment：B-chain
Chain C 90–110（21 aa） Fragment：A-chain
Chain D 25–54（30 aa） Fragment：B-chain
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.3；295 K；hydrochloric acid, zinc acetate, sodium citrate, acetone, pH 6.3, SLOW COOLING, temperature 295.0K
Resolution 1.95 Å R-free 0.253
1OS4 Dehydrated T6 human insulin at 295 K Deposited 2003-03-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：A-chain
Chain B 25–54（30 aa） Fragment：B-chain
Chain C 90–110（21 aa） Fragment：A-chain
Chain D 25–54（30 aa） Fragment：B-chain
Chain E 90–110（21 aa） Fragment：A-chain
Chain F 25–54（30 aa） Fragment：B-chain
Chain G 90–110（21 aa） Fragment：A-chain
Chain H 25–54（30 aa） Fragment：B-chain
Chain I 90–110（21 aa） Fragment：A-chain
Chain J 25–54（30 aa） Fragment：B-chain
Chain K 90–110（21 aa） Fragment：A-chain
Chain L 25–54（30 aa） Fragment：B-chain
Not recorded ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions SLOW COOLING；pH 6.3；295 K；hydrochloric acid, zinc acetate, sodium citrate, acetone, pH 6.3, SLOW COOLING, temperature 295.K
Resolution 2.25 Å R-free 0.295
1QIY HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH PHENOL Deposited 1999-06-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8；CRYSTALLISATION IN BATCH, 10 MG B5 TYR INSULIN DISSOLVED IN 2 ML 0.02M HCL. TO THIS ADDED 0.1 ML 0.12M ZINC ACETATE, 1.5 ML 0.2 M TRI-SODIUM CITRATE, 0.4 ML 2.5% (AQ.) PHENOL AND 120 MG NACL. PH ADJUSTED TO 6.5-7.8 .
Resolution 2.30 Å
1QIZ HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH RESORCINOL Deposited 1999-06-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES RCO RESORCINOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8；CRYSTALLISATION IN BATCH, 10 MG B5 TYR INSULIN DISSOLVED IN 2 ML 0.02M HCL. TO THIS ADDED 0.1 ML 0.12M ZINC ACETATE, 1.04 ML 0.2 M TRI-SODIUM CITRATE, 0.4 ML 5.0% (AQ.) PHENOL AND 120 MG NACL. PH ADJUSTED TO 6.5-7.8 .
Resolution 2.00 Å
1QJ0 HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR Deposited 1999-06-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：YES Mutation：YES ZN ZINC ION × 6 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8；CRYSTALLISATION IN BATCH: 10 MG B5 TYR INSULIN DISSOLVED IN 2 ML 0.02M HCL. TO THIS ADDED 0.05 ML 0.15M ZINC ACETATE, 1.0 ML 0.2 M TRI-SODIUM CITRATE, 1.0 ML ACETONE. PH ADJUSTED TO 6.4-7.1 .
Resolution 2.40 Å
1RWE Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues Deposited 2003-12-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa） Fragment：insulin A chain
Chain B 25–54（30 aa） Fragment：insulin B chain
Mutation：T8H ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8；298 K；Tris, sodium citrate, acetone, phenol, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 6.80
Resolution 1.80 Å R-free 0.245
1RWE Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues Deposited 2003-12-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa） Fragment：insulin A chain
Chain D 25–54（30 aa） Fragment：insulin B chain
Mutation：T8H ZN ZINC ION × 3 CL CHLORIDE ION × 3 IPH PHENOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8；298 K；Tris, sodium citrate, acetone, phenol, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 6.80
Resolution 1.80 Å R-free 0.245
1RWE Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues Deposited 2003-12-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：insulin A chain
Chain B 25–54（30 aa） Fragment：insulin B chain
Chain C 90–110（21 aa） Fragment：insulin A chain
Chain D 25–54（30 aa） Fragment：insulin B chain
Mutation：T8H Mutation：T8H ZN ZINC ION × 6 CL CHLORIDE ION × 6 IPH PHENOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.8；298 K；Tris, sodium citrate, acetone, phenol, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 6.80
Resolution 1.80 Å R-free 0.245
1SF1 NMR STRUCTURE OF HUMAN INSULIN under Amyloidogenic Condition, 15 STRUCTURES Deposited 2004-02-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 2.4；333 K；Pressure ambient
NMR sample composition 0.5 mM 15N-labeled sample | pH 2.4 and 60C, 90% H2O/10%D2O
Resolution not provided
1SJT MINI-PROINSULIN, TWO CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP, NMR, 20 STRUCTURES Deposited 1997-10-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：CHAIN B, DEL(A30), H10D, P28D Mutation：CHAIN B, DEL(A30), H10D, P28D No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1SJU MINI-PROINSULIN, SINGLE CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP AND PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1, NMR, 20 STRUCTURES Deposited 1997-10-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 25–110（86 aa）
Mutation：SINGLE CHAIN MUTANT WITH CHAIN B, DEL(A30), H10D, P28D, AND A PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1 OF THE WILD TYPE No recorded non-water small molecule SOLUTION NMR mmCIF provides none of the parsed conditions Resolution not provided
1T0C Solution Structure of Human Proinsulin C-Peptide Deposited 2004-04-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 57–87（31 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；283 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 3mM C-peptide | 50% H2O / 50% TFE-d2
Resolution not provided
1T1K NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2004-04-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain B 25–54（30 aa） Fragment：INSULIN B CHAIN
Mutation：HIS-B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS-B29-PRO No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR measurement conditions pH 7.6；305 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR measurement conditions pH 1.9；298 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR sample composition 1.2 mM Ala-B12-DKP-insulin, 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition 1.2 mM Ala-B12-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition 1.2 mM Ala-B12-DKP-insulin, 20% deuterated acetic acid, 80% D2O | 20% deuterated acetic acid, 80% D2O
Resolution not provided
1T1P NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2004-04-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：INSULIN A CHAIN
Chain B 25–54（30 aa） Fragment：INSULIN B CHAIN
Mutation：HIS-B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS-B29-PRO No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR measurement conditions pH 7.6；305 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR sample composition 1.2 mM Thr-B12-DKP-insulin, 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition 1.2 mM Thr-B12-DKP-insulin, 100% D2O | 100% D2O
Resolution not provided
1T1Q NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2004-04-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–21（21 aa） Fragment：INSULIN A CHAIN
Chain B 25–54（30 aa） Fragment：INSULIN B CHAIN
Mutation：HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Pressure ambient
NMR measurement conditions pH 7.6；305 K；Pressure ambient
NMR sample composition 1.2 mM ABA-B12-DKP-insulin, 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition 1.2 mM ABA-B12-DKP-insulin,100% D2O | 100% D2O
Resolution not provided
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 3 NA SODIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
Resolution 1.60 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 1 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Not recorded ZN ZINC ION × 3 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 3 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 1 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 3 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1UZ9 Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting insulins. Deposited 2004-03-08 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：INSULIN A CHAIN, RESIDUES 90-110
Chain B 25–53（29 aa） Fragment：INSULIN B CHAIN, RESIDUES 25-53
Not recorded CRS M-CRESOL × 6 UZ9 (2S)-2-AMINO-6-({(4R)-4-[(10R,13S)-10,13-DIMETHYL-3-OXOHEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL]PENTANOYL}AMINO)HEXANOIC ACID × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.5 M TRIS-HCL PH 8.0 0.1M TRI-SODIUM CITRATE, 2MM ZINC ACETATE, 0.05% W/V M-CRESOL
Resolution 1.60 Å R-free 0.206
1VKT HUMAN INSULIN TWO DISULFIDE MODEL, NMR, 10 STRUCTURES Deposited 1996-10-14 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：CHAIN A, C6S, C11S, CHAIN B, H10D, P28K, K29P Mutation：CHAIN A, C6S, C11S, CHAIN B, H10D, P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.8；298 K
Resolution not provided
1W8P Structural properties of the B25Tyr-NMe-B26Phe insulin mutant. Deposited 2004-09-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES IPH PHENOL × 6 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.1 M TRI-SODIUM CITRATE, 0.02 % W/V ZINC ACETATE, 6 % W/V TRIS/HCL PH 8.2, 0.1 % W/V PHENOL.
Resolution 2.08 Å R-free 0.256
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 10 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 11 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 12 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Not recorded IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
Resolution 1.80 Å
1XGL HUMAN INSULIN DISULFIDE ISOMER, NMR, 10 STRUCTURES Deposited 1996-10-10 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–51（21 aa）
Chain B 1–30（30 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K
Resolution not provided
1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：V3L IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
Resolution 2.30 Å R-free 0.269
1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：V3L IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
Resolution 2.30 Å R-free 0.269
1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：V3L Mutation：V3L IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
Resolution 2.30 Å R-free 0.269
1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：V3L Mutation：V3L IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
Resolution 2.30 Å R-free 0.269
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 2 ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 9 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 3 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 3 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain A 90–110（21 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 6 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 9 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 6 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
Resolution 1.60 Å R-free 0.192
1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D CRS M-CRESOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
Resolution 1.50 Å R-free 0.193
1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D CRS M-CRESOL × 4 ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
Resolution 1.50 Å R-free 0.193
1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D CRS M-CRESOL × 15 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
Resolution 1.50 Å R-free 0.193
1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D CRS M-CRESOL × 5 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
Resolution 1.50 Å R-free 0.193
1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D CRS M-CRESOL × 5 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
Resolution 1.50 Å R-free 0.193
1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 31–51（21 aa）
Chain B 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D CRS M-CRESOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
Resolution 1.50 Å R-free 0.193
1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 31–51（21 aa）
Chain D 25–54（30 aa）
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D CRS M-CRESOL × 12 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
Resolution 1.50 Å R-free 0.193
1ZNJ INSULIN, MONOCLINIC CRYSTAL FORM Deposited 1997-09-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded IPH PHENOL × 7 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions batch method；pH 7.44；BATCH, 1.7MG/ML INSULIN, 0.02 ZINC ACETATE, 0.7% (V/V) PHENOL, 0.34M SODIUM CHLORIDE, pH 7.44, batch method
Resolution 2.00 Å
25HF SFX crystal structure of insulin aspart Deposited 2026-04-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded CRS M-CRESOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium acetate trihydrate, pH 8.5, 0.1 M Tris-HCl.
Resolution 2.20 Å R-free 0.289
25HL SFX crystal structure of insulin detemir Deposited 2026-04-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium acetate trihydrate, pH 8.5, 0.1 M Tris-HCl
Resolution 2.85 Å R-free 0.285
25HL SFX crystal structure of insulin detemir Deposited 2026-04-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium acetate trihydrate, pH 8.5, 0.1 M Tris-HCl
Resolution 2.85 Å R-free 0.285
2AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 20 STRUCTURES Deposited 1998-12-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：ALPHA CHAIN
Chain B 25–54（30 aa） Fragment：BETA CHAIN
Chain C 90–110（21 aa） Fragment：ALPHA CHAIN
Chain D 25–54（30 aa） Fragment：BETA CHAIN
Chain E 90–110（21 aa） Fragment：ALPHA CHAIN
Chain F 25–54（30 aa） Fragment：BETA CHAIN
Chain G 90–110（21 aa） Fragment：ALPHA CHAIN
Chain H 25–54（30 aa） Fragment：BETA CHAIN
Chain I 90–110（21 aa） Fragment：ALPHA CHAIN
Chain J 25–54（30 aa） Fragment：BETA CHAIN
Chain K 90–110（21 aa） Fragment：ALPHA CHAIN
Chain L 25–54（30 aa） Fragment：BETA CHAIN
Not recorded IPH PHENOL × 6 SOLUTION NMR
NMR measurement conditions pH 8；310 K；Pressure 1
NMR sample composition H2O AND D2O
Resolution not provided
2C8Q insuline(1sec) and UV laser excited fluorescence Deposited 2005-12-06 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 9；pH 9.00
Resolution 1.95 Å R-free 0.230
2C8R insuline(60sec) and UV laser excited fluorescence Deposited 2005-12-06 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 9；pH 9.00
Resolution 1.50 Å R-free 0.224
2CEU Despentapeptide insulin in acetic acid (pH 2) Deposited 2006-02-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–49（25 aa）
Chain C 90–110（21 aa）
Chain D 25–49（25 aa）
Not recorded SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 2；20 % ACETIC ACID, 0.05 M SODIUM SULPHATE, PH 2
Resolution 1.80 Å R-free 0.211
2G54 Crystal structure of Zn-bound human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 25–54（30 aa） Fragment：Insulin B chain, residues 25-54
Not recorded ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, HEPES buffer, tacismate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.25 Å R-free 0.233
2G54 Crystal structure of Zn-bound human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 25–54（30 aa） Fragment：Insulin B chain, residues 25-54
Not recorded ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, HEPES buffer, tacismate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.25 Å R-free 0.233
2G56 crystal structure of human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain C 25–54（30 aa） Fragment：Insulin B chain, residues 25-54
Not recorded DIO 1,4-DIETHYLENE DIOXIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, tacismate, hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.20 Å R-free 0.225
2G56 crystal structure of human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 25–54（30 aa） Fragment：Insulin B chain, residues 25-54
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, tacismate, hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.20 Å R-free 0.225
2H67 NMR structure of human insulin mutant HIS-B5-ALA, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures Deposited 2006-05-30 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：H29A,H34D,P52K, K53P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K
NMR measurement conditions pH 8；305 K
NMR measurement conditions pH 2；298 K；Ionic strength (raw mmCIF value) 20% acetic acid
Resolution not provided
2HHO NMR structure of human insulin mutant GLY-B8-SER, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures Deposited 2006-06-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：G8S, H10D, P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K
Resolution not provided
2HIU NMR STRUCTURE OF HUMAN INSULIN IN 20% ACETIC ACID, ZINC-FREE, 10 STRUCTURES Deposited 1996-10-08 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K
Resolution not provided
2JMN NMR structure of human insulin mutant His-B10-Asp, Pro-B28-Lys, Lys-B29-Pro, 20 structures Deposited 2006-11-21 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：H10D, P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K
NMR sample composition 0.7 mM INSULIN, 90% H2O, 10% D2O | 90% H2O/10% D2O
Resolution not provided
2JUM ThrA3-DKP-insulin Deposited 2007-08-31 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：V3T Mutation：H10D,P28K,K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；308 K；Pressure ambient
NMR measurement conditions pH 7；308 K；Pressure ambient
NMR measurement conditions pH 8；315 K；Pressure ambient
NMR measurement conditions pH 1.9；308 K；Pressure ambient
NMR measurement conditions pH 1.9；308 K；Pressure ambient
NMR sample composition 1 mM ThrA3-DKP-insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 1 mM ThrA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition 1 mM ThrA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition 1 mM ThrA3-DKP-insulin, 3.1 M D-acetic acid, 20% D-acetic acid/80% H2O | 20% D-acetic acid/80% H2O
NMR sample composition 1 mM ThrA3-DKP-insulin, 3.1 M D-acetic acid, 20%D-acetic acid/80% D2O | 20%D-acetic acid/80% D2O
Resolution not provided
2JUU allo-ThrA3 DKP-insulin Deposited 2007-09-03 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：V3T Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：H10D,P28K,K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；308 K；Pressure ambient
NMR measurement conditions pH 8；315 K；Pressure ambient
NMR measurement conditions pH 1.9；308 K；Pressure ambient
NMR sample composition 1 mM allo-ThrA3 DKP-insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 1 mM allo-ThrA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition 1 mM allo-ThrA3 DKP-insulin, 100% D2O | 100% D2O
NMR sample composition 1 mM allo-ThrA3 DKP-insulin, 3.1 M D-acetic acid, 20% D-acetic acid/80% H2O | 20% D-acetic acid/80% H2O
NMR sample composition 1 mM ThrA3-DKP-insulin, 3.1 M D-acetic acid, 20%D-acetic acid/80% D2O | 20%D-acetic acid/80% D2O
Resolution not provided
2JUV AbaA3-DKP-insulin Deposited 2007-09-05 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：V3T Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：H10D,P28K,K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；308 K；Pressure ambient
NMR measurement conditions pH 8；315 K；Pressure ambient
NMR measurement conditions pH 1.9；308 K；Pressure ambient
NMR sample composition 1 mM AbaA3-DKP-insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 1 mM AbaA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition 1 mM AbaA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition 1 mM AbaA3-DKP-insulin, 20% D-acetic acid/80% H2O | 20% D-acetic acid/80% H2O
NMR sample composition 1 mM AbaA3-DKP-insulin, 20%D-acetic acid/80% D2O | 20%D-acetic acid/80% D2O
Resolution not provided
2JV1 NMR structure of human insulin monomer in 35% CD3CN zinc free, 50 structures Deposited 2007-09-11 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：Insulin A chain: Residues 90-110
Chain B 25–54（30 aa） Fragment：Insulin B chain: Residues 25-54
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 3.6；303 K；Ionic strength (raw mmCIF value) None；Pressure ambient
NMR sample composition 2.0 mM Insulin_chain_A, 2.0 mM Insulin_chain_B, 35% CD3CN/ 65%H2O | 35% CD3CN/ 65%H2O
Resolution not provided
2JZQ Design of an Active Ultra-Stable Single-Chain Insulin Analog 20 Structures Deposited 2008-01-11 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 25–54（30 aa）
Chain A 90–110（21 aa）
Mutation：H34D, P52D, K53P, T97H Mutation：H34D, P52D, K53P, T97H No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 8；305 K；Pressure ambient
NMR sample composition 0.5-0.8 mM protein, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2K91 Enhancing the activity of insulin by stereospecific unfolding Deposited 2008-09-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Mutation：H10D, F24A, P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7.4；298 K；Pressure AMBIENT
NMR sample composition 0.5-0.8 MM PROTEIN, 90% H2O/ 10% D2O AND 20% ACETIC ACID
Resolution not provided
2K9R Enhancing the activity of insulin by stereospecific unfolding Deposited 2008-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：Insulin A chain
Chain B 25–54（30 aa） Fragment：Insulin B chain
Mutation：H10D, F24A, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7.4；298 K；Ionic strength (raw mmCIF value) 0；Pressure AMBIENT
NMR sample composition 0.5-0.8 mM INSULIN A CHAIN, 0.5-0.8 mM INSULIN B CHAIN, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2KJJ Dynamics of insulin probed by 1H-NMR amide proton exchange anomalous flexibility of the receptor-binding surface Deposited 2009-05-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：Insulin A chain, UNP residues 90-110
Chain B 25–54（30 aa） Fragment：Insulin B chain, UNP residues 25-54
Mutation：P28K,K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7.4；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure AMBIENT
NMR sample composition 0.5 mM INSULIN A CHAIN-1, 0.5 mM INSULIN B CHAIN-2, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2KJU NMR structure of human insulin mutant glu-b21-d-glu, his-b10 asp pro-b28-lys, lys-b29-pro, 20 structures Deposited 2009-06-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：Insulin A chain, residues 90-110
Chain B 25–54（30 aa） Fragment：Insulin B chain, residues 25-54
Mutation：HIS10ASP, GLU21DGL, PRO28LYS, LYS29PRO Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR measurement conditions pH 2；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR measurement conditions pH 7.6；305 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR sample composition 0.5 mM INSULIN A CHAIN, 0.5 mM INSULIN B CHAIN, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2KQP NMR Structure of Proinsulin Deposited 2009-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 25–110（86 aa）
Mutation：H10D, P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7.1；298 K；Pressure ambient
NMR sample composition 0.3 mM [U-100% 13C; U-100% 15N] proinsulin-1, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2KQQ NMR structure of human insulin mutant gly-b8-d-ala, his-b10-asp, pro-b28-lys, lys-b29-pro, 20 structures Deposited 2009-11-13 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：G8Dal, H10D, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 0；Pressure AMBIENT
NMR sample composition 0.5-0.8 mM entity_1-1, 0.5-0.8 mM entity_2-2, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2KXK Human Insulin Mutant A22Gly-B31Lys-B32Arg Deposited 2010-05-07 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：R31K No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 3.5；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 2.5 mM protein_1 and protein_2-1, 65% H2O / 35% CD3CN | 65% H2O / 35% CD3CN
NMR sample composition 2.5 mM protein_1 and protein_2-2, 65% D2O / 35% CD3CN | 65% D2O / 35% CD3CN
Resolution not provided
2L1Y NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures Deposited 2010-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：UNP rsidues 90-110
Chain B 25–54（30 aa） Fragment：UNP rsidues 25-54
Mutation：P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K
NMR sample composition 0.5 mM entity_1-1, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2L1Z NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures Deposited 2010-08-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K
NMR sample composition 0.5 mM entity_1-1, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2LGB Modified A22Gly-B31Arg Human Insulin Deposited 2011-07-25 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–55（31 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 3.5；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 3.0 - 2.0 mM Insulin A chain, 3.0 - 2.0 mM Insulin B chain, 65% H2O / 35% CD3CN | 65% H2O / 35% CD3CN
NMR sample composition 3.0 - 2.0 mM Insulin A chain, 3.0 - 2.0 mM Insulin B chain, 65% D2O / 35% CD3CN | 65% D2O / 35% CD3CN
Resolution not provided
2LWZ NMR Structures of Single-chain Insulin Deposited 2012-08-09 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 25–54（30 aa）
Chain A 89–110（22 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure ambient
NMR sample composition 0.9 mM [U-100% 13C; U-100% 15N] insulin, 93% H2O/7% D2O | 93% H2O/7% D2O
Resolution not provided
2M1D Biosynthetic engineered B28K-B29P human insulin monomer structure in in water/acetonitrile solutions. Deposited 2012-11-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 2.5；298 K；Ionic strength (raw mmCIF value) 1；Pressure ambient
NMR sample composition 2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % H2O, 27 % CD3CN, H2O / CD3CN | H2O / CD3CN
NMR sample composition 2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % D2O-7, 27 % CD3CN-8, D2O / CD3CN | D2O / CD3CN
Resolution not provided
2M1E Biosynthetic engineered B28K-B29P human insulin monomer structure in in water solutions. Deposited 2012-11-26 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：P28K, K29P No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 2.5；298 K；Ionic strength (raw mmCIF value) 1；Pressure ambient
NMR sample composition 2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 100% D2O | 100% D2O
Resolution not provided
2M2M Structure of [L-HisB24] insulin analogue at pH 1.9 Deposited 2012-12-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：F24H No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 0.250 mM protein_1, 20% [U-99% 2H] acetic acid, 0.250 mM protein_2, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
2M2N Structure of [L-HisB24] insulin analogue at pH 8.0 Deposited 2012-12-29 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：F24H No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 8；298 K；Ionic strength (raw mmCIF value) 0.025；Pressure ambient
NMR sample composition 0.250 mM chain_A, 0.250 mM chain_B, 25 mM [U-99% 2H] TRIS, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
2M2O Structure of [D-HisB24] insulin analogue at pH 1.9 Deposited 2012-12-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa） Fragment：F24(D-HIS)
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 0.250 mM chain_A, 0.250 mM chain_B, 20% [U-2H] acetic acid, 95% H2O/5% D2O
Resolution not provided
2M2P Structure of [D-HisB24] insulin analogue at pH 8.0 Deposited 2012-12-29 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：F24(D-HIS) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 8；298 K；Ionic strength (raw mmCIF value) 0.025；Pressure ambient
NMR sample composition 0.250 mM chain_A, 0.250 mM chain_B, 25 mM [U-2H] TRIS, 95% H2O/5% D2O
Resolution not provided
2MLI NMR structure of B25-(alpha, beta)-dehydro-phenylalanine insulin Deposited 2014-02-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：A chain (UNP residues 90-110)
Chain B 25–54（30 aa） Fragment：B chain (UNP residues 25-54)
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 0.01；Pressure ambient
NMR measurement conditions pH 7；298 K；Ionic strength (raw mmCIF value) 0.01
NMR sample composition 0.5 mM [U-13C; U-15N] insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.5 mM insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2MPG Solution structure of the [AibB8,LysB28,ProB29]-insulin analogue Deposited 2014-05-17 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：G32X,P52K,K53P Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 0.3 mM protein_1, 20 % [U-2H] acetic acid, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
2MPI Solution structure of B24G insulin Deposited 2014-05-19 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：K53P P52K F48G H34D No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 8；305 K；Ionic strength (raw mmCIF value) 0.5；Pressure ambient
NMR sample composition 0.3 mM protein, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.3 mM protein, 100% D2O | 100% D2O
Resolution not provided
2MVC Solution structure of human insulin at pH 1.9 Deposited 2014-10-02 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 4 mM protein_1, 4 mM protein_2, 20 % [U-99% 2H] acetic acid, 5 % [U-99% 2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
2MVD Solution structure of [GlnB22]-insulin mutant at pH 1.9 Deposited 2014-10-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Mutation：R46Q No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 0.2 mM protein_1, 0.2 mM protein_2, 20 % [U-99% 2H] acetic acid, 5 % [U-99% 2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
2N2V Solution structure of [B26-B29 triazole cross-linked]-insulin analogue at pH 1.9 Deposited 2015-05-15 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：Y26(NVA), K29(HIX) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 1.5 mM chain_A, 1.5 mM chain_B, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2N2W Solution structure of [B26-B29 triazole cross-linked]-insulin analogue at pH 8.0 Deposited 2015-05-15 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：Y26(NVA), K29(HIX) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 8；298 K；Pressure ambient
NMR sample composition 1.5 mM chain_A, 1.5 mM chain_B, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2N2X Solution structure of [GlyB24,B27-B29 triazole cross-linked]-insulin analogue at pH 1.9 Deposited 2015-05-15 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：Y26(NVA), K29(HIX) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 1.9；298 K；Pressure ambient
NMR sample composition 1.5 mM chain_A, 1.5 mM chain_B, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2OLY Structure of human insulin in presence of urea at pH 7.0 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded RCO RESORCINOL × 8 URE UREA × 7 ZN ZINC ION × 2 CL CHLORIDE ION × 5 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；2.5M NaCl, 4M urea, 100mM phosphate buffer, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.70 Å R-free 0.221
2OLZ Structure of human insulin in presence of thiocyanate at pH 7.0 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.70 Å R-free 0.221
2OM0 Structure of human insulin in presence of urea at pH 6.5 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 URE UREA × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；2M NaCl, 3M urea, 100mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.05 Å R-free 0.227
2OM0 Structure of human insulin in presence of urea at pH 6.5 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain 1 90–110（21 aa）
Chain 2 25–54（30 aa）
Chain 3 90–110（21 aa）
Chain 4 25–54（30 aa）
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Chain X 90–110（21 aa）
Chain Y 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 URE UREA × 4 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；2M NaCl, 3M urea, 100mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.05 Å R-free 0.227
2OM0 Structure of human insulin in presence of urea at pH 6.5 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain a 90–110（21 aa）
Chain b 25–54（30 aa）
Chain c 90–110（21 aa）
Chain d 25–54（30 aa）
Chain e 90–110（21 aa）
Chain f 25–54（30 aa）
Chain g 90–110（21 aa）
Chain h 25–54（30 aa）
Chain i 90–110（21 aa）
Chain j 25–54（30 aa）
Chain k 90–110（21 aa）
Chain l 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 URE UREA × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；2M NaCl, 3M urea, 100mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.05 Å R-free 0.227
2OM1 Structure of human insulin in presence of thiocyanate at pH 6.5 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.97 Å R-free 0.212
2OM1 Structure of human insulin in presence of thiocyanate at pH 6.5 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain 1 90–110（21 aa）
Chain 2 25–54（30 aa）
Chain 3 90–110（21 aa）
Chain 4 25–54（30 aa）
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Chain X 90–110（21 aa）
Chain Y 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.97 Å R-free 0.212
2OM1 Structure of human insulin in presence of thiocyanate at pH 6.5 Deposited 2007-01-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain a 90–110（21 aa）
Chain b 25–54（30 aa）
Chain c 90–110（21 aa）
Chain d 25–54（30 aa）
Chain e 90–110（21 aa）
Chain f 25–54（30 aa）
Chain g 90–110（21 aa）
Chain h 25–54（30 aa）
Chain i 90–110（21 aa）
Chain j 25–54（30 aa）
Chain k 90–110（21 aa）
Chain l 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.97 Å R-free 0.212
2OMG Structure of human insulin cocrystallized with protamine and urea Deposited 2007-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 2 CRS M-CRESOL × 6 URE UREA × 12 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；60mM m-cresol, 3M urea, 1.0 mg/ml protamine sulphate, 400mM NaCl, 40mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.52 Å R-free 0.209
2OMH Structure of human insulin cocrystallized with ARG-12 peptide in presence of urea Deposited 2007-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Not recorded NA SODIUM ION × 2 RCO RESORCINOL × 6 URE UREA × 8 ZN ZINC ION × 2 CL CHLORIDE ION × 2 ARF FORMAMIDE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；500mM NaCl, 2.5M urea, 1.2mg/ml ARG-12 peptide, 50mM resorcinol, 50mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.36 Å R-free 0.223
2OMH Structure of human insulin cocrystallized with ARG-12 peptide in presence of urea Deposited 2007-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Not recorded NA SODIUM ION × 2 RCO RESORCINOL × 6 URE UREA × 8 ZN ZINC ION × 2 CL CHLORIDE ION × 2 ARF FORMAMIDE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；500mM NaCl, 2.5M urea, 1.2mg/ml ARG-12 peptide, 50mM resorcinol, 50mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.36 Å R-free 0.223
2OMI Structure of human insulin cocrystallized with protamine Deposited 2007-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；50mM resorcinol, 400mM NaCl, 1.0mg/ml protamine 30mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.24 Å R-free 0.268
2QIU Structure of Human Arg-Insulin Deposited 2007-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 89–110（22 aa） Fragment：Insulin A chain
Chain B 25–54（30 aa） Fragment：Insulin B chain
Chain C 89–110（22 aa） Fragment：Insulin A chain
Chain D 25–54（30 aa） Fragment：Insulin B chain
Not recorded ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Acetone, Zinc Sulphate, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.249
2R34 Crystal structure of MN human arg-insulin Deposited 2007-08-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 89–110（22 aa） Fragment：Insulin A chain
Chain B 25–54（30 aa） Fragment：Insulin B chain
Chain C 89–110（22 aa） Fragment：Insulin A chain
Chain D 25–54（30 aa） Fragment：Insulin B chain
Not recorded MN MANGANESE (II) ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Ammonium Sulphate, Magnesium Chloride, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.25 Å R-free 0.264
2R35 Crystal structure of RB human arg-insulin Deposited 2007-08-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 89–110（22 aa） Fragment：Insulin A chain
Chain B 25–54（30 aa） Fragment：Insulin B chain
Chain C 89–110（22 aa） Fragment：Insulin A chain
Chain D 25–54（30 aa） Fragment：Insulin B chain
Not recorded NA SODIUM ION × 3 RB RUBIDIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Acetone, Rubidium Chloride, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.08 Å R-free 0.298
2R36 Crystal structure of ni human ARG-insulin Deposited 2007-08-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 89–110（22 aa） Fragment：Insulin A chain
Chain B 25–54（30 aa） Fragment：Insulin B chain
Chain C 89–110（22 aa） Fragment：Insulin A chain
Chain D 25–54（30 aa） Fragment：Insulin B chain
Not recorded NI NICKEL (II) ION × 12 NA SODIUM ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Ammonium Sulphate, Nickel Chloride, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.255
2RN5 Humal Insulin Mutant B31Lys-B32Arg Deposited 2007-12-06 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 3.6；300 K；Pressure ambient
NMR sample composition 2.0mM Insulin (chain A), 2.0mM Insulin (chain B), 35% CD3CN, 65% D2O, CD3CN/D2O | CD3CN/D2O
NMR sample composition 2.0mM Insulin (chain A), 2.0mM Insulin (chain B), 35% CD3CN, 65% H2O, CD3CN/H2O | CD3CN/H2O
Resolution not provided
2VJZ Crystal structure form ultalente insulin microcrystals Deposited 2007-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：RESIDUES 90-110
Chain B 25–54（30 aa） Fragment：RESIDUES 25-54
Chain C 90–110（21 aa） Fragment：RESIDUES 90-110
Chain D 25–54（30 aa） Fragment：RESIDUES 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 12 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 1.80 Å R-free 0.239
2VK0 Crystal structure form ultalente insulin microcrystals Deposited 2007-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：RESIDUES 90-110
Chain B 25–54（30 aa） Fragment：RESIDUES 25-54
Chain C 90–110（21 aa） Fragment：RESIDUES 90-110
Chain D 25–54（30 aa） Fragment：RESIDUES 25-54
Not recorded ZN ZINC ION × 12 MPB 4-HYDROXY-BENZOIC ACID METHYL ESTER × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；pH 5.5
Resolution 2.20 Å R-free 0.282
2WBY Crystal structure of human insulin-degrading enzyme in complex with insulin Deposited 2009-03-06 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 90–109（20 aa） Fragment：RESIDUES 90-109
Chain D 25–43（19 aa） Fragment：RESIDUES 25-43
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE
Resolution 2.60 Å R-free 0.218
2WBY Crystal structure of human insulin-degrading enzyme in complex with insulin Deposited 2009-03-06 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain E 90–109（20 aa） Fragment：RESIDUES 90-109
Chain F 25–43（19 aa） Fragment：RESIDUES 25-43
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE
Resolution 2.60 Å R-free 0.218
2WC0 crystal structure of human insulin degrading enzyme in complex with iodinated insulin Deposited 2009-03-06 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 90–110（21 aa） Fragment：RESIDUES 90-110
Chain D 25–54（30 aa） Fragment：RESIDUES 25-54
Not recorded ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；pH 7
Resolution 2.80 Å R-free 0.220
2WC0 crystal structure of human insulin degrading enzyme in complex with iodinated insulin Deposited 2009-03-06 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain E 90–110（21 aa） Fragment：RESIDUES 90-110
Chain F 25–54（30 aa） Fragment：RESIDUES 25-54
Not recorded ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；pH 7
Resolution 2.80 Å R-free 0.220
2WRU Semi-synthetic highly active analogue of human insulin NMeAlaB26-DTI- NH2 Deposited 2009-09-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa） Fragment：RESIDUES 25-50
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) ACT ACETATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 3；0.32 M NA2SO4, PH 3.0
Resolution 1.57 Å R-free 0.255
2WRV Semi-synthetic highly active analogue of human insulin NMeHisB26-DTI- NH2 Deposited 2009-09-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa） Fragment：RESIDUES 25-50
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；0.1 NA CITRATE, 0.3 M TRIS PH 8.2, 0.6 MM ZN ACETATE, 0.06% PHENOL
Resolution 2.15 Å R-free 0.277
2WRW Semi-synthetic highly active analogue of human insulin D-ProB26-DTI- NH2 Deposited 2009-09-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa） Fragment：RESIDUES 25-50
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 3；0.015 M CS2SO4 PH 3.0
Resolution 2.41 Å R-free 0.301
2WRX Semi-synthetic analogue of human insulin NMeAlaB26-insulin at pH 3.0 Deposited 2009-09-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 3；0.18 M LI2SO4, 0.1M NA ACETATE PH 3.0
Resolution 1.50 Å R-free 0.251
2WS0 Semi-synthetic analogue of human insulin NMeAlaB26-insulin at pH 7.5 Deposited 2009-09-03 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；0.75 DILUTION IN WATER OF STOCK OF 0.1 M NA CITRATE,0.3M TRIS PH 7.5,0.6 MM ZN ACETATE, 0.06% PHENOL
Resolution 2.10 Å R-free 0.337
2WS1 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in monomer form Deposited 2009-09-03 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 3；0.055 M NA2SO4 PH 3.0
Resolution 1.60 Å R-free 0.248
2WS4 Semi-synthetic analogue of human insulin ProB26-DTI in monomer form Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa） Fragment：RESIDUES 25-50
Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 3；0.055M NA2SO4 PH 3.0
Resolution 1.90 Å R-free 0.278
2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 CL CHLORIDE ION × 2 ZN ZINC ION × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
Resolution 1.50 Å R-free 0.200
2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 3 CL CHLORIDE ION × 1 ZN ZINC ION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
Resolution 1.50 Å R-free 0.200
2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 3 CL CHLORIDE ION × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
Resolution 1.50 Å R-free 0.200
2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded IPH PHENOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
Resolution 1.50 Å R-free 0.200
2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 2 CL CHLORIDE ION × 2 ZN ZINC ION × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
Resolution 1.50 Å R-free 0.200
2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
Resolution 1.50 Å R-free 0.200
2WS7 Semi-synthetic analogue of human insulin ProB26-DTI Deposited 2009-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa） Fragment：RESIDUES 25-50
Chain C 90–110（21 aa）
Chain D 25–50（26 aa） Fragment：RESIDUES 25-50
Chain E 90–110（21 aa）
Chain F 25–50（26 aa） Fragment：RESIDUES 25-50
Chain G 90–110（21 aa）
Chain H 25–50（26 aa） Fragment：RESIDUES 25-50
Chain I 90–110（21 aa）
Chain J 25–50（26 aa） Fragment：RESIDUES 25-50
Chain K 90–110（21 aa）
Chain L 25–50（26 aa） Fragment：RESIDUES 25-50
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；5 MM ZN ACETATE,35 MM NA CITRATE,0.7% PHENOL,).7M NACL,0.3M TRIS PH 7.5
Resolution 2.59 Å R-free 0.332
3AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, REFINED AVERAGE STRUCTURE Deposited 1998-12-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：ALPHA CHAIN
Chain B 25–54（30 aa） Fragment：BETA CHAIN
Chain C 90–110（21 aa） Fragment：ALPHA CHAIN
Chain D 25–54（30 aa） Fragment：BETA CHAIN
Chain E 90–110（21 aa） Fragment：ALPHA CHAIN
Chain F 25–54（30 aa） Fragment：BETA CHAIN
Chain G 90–110（21 aa） Fragment：ALPHA CHAIN
Chain H 25–54（30 aa） Fragment：BETA CHAIN
Chain I 90–110（21 aa） Fragment：ALPHA CHAIN
Chain J 25–54（30 aa） Fragment：BETA CHAIN
Chain K 90–110（21 aa） Fragment：ALPHA CHAIN
Chain L 25–54（30 aa） Fragment：BETA CHAIN
Not recorded IPH PHENOL × 6 SOLUTION NMR
NMR measurement conditions pH 8；310 K；Pressure 1
NMR sample composition H2O AND D2O
Resolution not provided
3BXQ The structure of a mutant insulin uncouples receptor binding from protein allostery. An electrostatic block to the TR transition Deposited 2008-01-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：R29H Mutation：R29H ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.30 Å R-free 0.232
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Y Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.212
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3E7Z Structure of human insulin Deposited 2008-08-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å R-free 0.271
3EXX Structure of the T6 human insulin derivative with nickel at 1.35 A resolution Deposited 2008-10-17 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded NI NICKEL (II) ION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；1 mM sodium citrate, 10% acetone, 15 mM nickel(II) acetate tetrahydrate, pH 6.4, vapor diffusion, hanging drop, temperature 291K
Resolution 1.35 Å R-free 0.171
3EXX Structure of the T6 human insulin derivative with nickel at 1.35 A resolution Deposited 2008-10-17 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded NI NICKEL (II) ION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；1 mM sodium citrate, 10% acetone, 15 mM nickel(II) acetate tetrahydrate, pH 6.4, vapor diffusion, hanging drop, temperature 291K
Resolution 1.35 Å R-free 0.171
3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 91–110（20 aa）
Chain B 25–54（30 aa）
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
Resolution 1.35 Å R-free 0.228
3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 91–110（20 aa）
Chain D 25–54（30 aa）
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
Resolution 1.35 Å R-free 0.228
3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 91–110（20 aa）
Chain B 25–54（30 aa）
Chain C 91–110（20 aa）
Chain D 25–54（30 aa）
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
Resolution 1.35 Å R-free 0.228
3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 91–110（20 aa）
Chain B 25–54（30 aa）
Chain C 91–110（20 aa）
Chain D 25–54（30 aa）
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
Resolution 1.35 Å R-free 0.228
3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 91–110（20 aa）
Chain B 25–54（30 aa）
Chain C 91–110（20 aa）
Chain D 25–54（30 aa）
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
Resolution 1.35 Å R-free 0.228
3HYD LVEALYL peptide derived from human insulin chain B, residues 11-17 Deposited 2009-06-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 35–41（7 aa） Fragment：UNP residues 34-41 of chain B
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；20% MPD, 0.1M sodium citrate pH 5.5, vapor diffusion, hanging drop, temperature 298K
Resolution 1.00 Å R-free 0.180
3I3Z Human insulin Deposited 2009-07-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.195
3I40 Human insulin Deposited 2009-07-01 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.85 Å R-free 0.228
3ILG Crystal structure of humnan insulin Sr+2 complex Deposited 2009-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded SR STRONTIUM ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.1M Sodium Citrate, 1M Ammonium Sulphate, 0.1M Strontium Chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
Resolution 1.90 Å R-free 0.278
3INC Crystal structure of human insulin with Ni+2 complex Deposited 2009-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded NI NICKEL (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；298 K；0.2M Sodium Citrate, 0.12M Nickel Chloride, 1M Ammonium Sulphate, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.257
3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded CU COPPER (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.299
3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Not recorded CU COPPER (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.299
3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded CU COPPER (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.299
3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Not recorded CU COPPER (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.299
3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain R 90–110（21 aa）
Chain S 25–54（30 aa）
Chain T 90–110（21 aa）
Chain U 25–54（30 aa）
Not recorded CU COPPER (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.299
3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain V 90–110（21 aa）
Chain W 25–54（30 aa）
Chain X 90–110（21 aa）
Chain Y 25–54（30 aa）
Not recorded CU COPPER (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.299
3JSD Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2009-09-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 6 CL CHLORIDE ION × 6 IPH PHENOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；298 K；0.02M Tris-HCl, 0.05M Sodium citrate, 5% Acetone, 0.03% Phenol, 0.01% Zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
Resolution 2.50 Å R-free 0.274
3KQ6 Enhancing the Therapeutic Properties of a Protein by a Designed Zinc-Binding Site, Structural principles of a novel long-acting insulin analog Deposited 2009-11-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：E4H, T4H Mutation：E4H, T4H ZN ZINC ION × 9 CL CHLORIDE ION × 6 IPH PHENOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
Resolution 1.90 Å R-free 0.257
3P2X Insulin fibrillation is the Janus face of induced fit. A chiaral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa） Fragment：unp residues 90-110
Chain B 25–54（30 aa） Fragment：unp residues 25-54
Mutation：G32(DAL) Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.314
3P2X Insulin fibrillation is the Janus face of induced fit. A chiaral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa） Fragment：unp residues 90-110
Chain D 25–54（30 aa） Fragment：unp residues 25-54
Mutation：G32(DAL) Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 3 CL CHLORIDE ION × 3 IPH PHENOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.314
3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa） Fragment：unp residues 90-110
Chain B 25–54（30 aa） Fragment：unp residues 25-54
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.299
3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa） Fragment：unp residues 90-110
Chain D 25–54（30 aa） Fragment：unp residues 25-54
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.299
3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain E 90–110（21 aa） Fragment：unp residues 90-110
Chain F 25–54（30 aa） Fragment：unp residues 25-54
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.299
3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain G 90–110（21 aa） Fragment：unp residues 90-110
Chain H 25–54（30 aa） Fragment：unp residues 25-54
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.299
3Q6E Human insulin in complex with cucurbit[7]uril Deposited 2010-12-31 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：unp residues 90-110
Chain B 25–54（30 aa） Fragment：unp residues 25-54
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 7；298 K；40 uM Q7, 40 uM insulin, 10 mM sodium phosphate, 4 mM EDTA, 1 mM lysine, EVAPORATION, temperature 298K, pH 7.0
Resolution 2.05 Å R-free 0.253
3Q6E Human insulin in complex with cucurbit[7]uril Deposited 2010-12-31 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa） Fragment：unp residues 90-110
Chain D 25–54（30 aa） Fragment：unp residues 25-54
Not recorded QQ7 cucurbit[7]uril × 1 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 7；298 K；40 uM Q7, 40 uM insulin, 10 mM sodium phosphate, 4 mM EDTA, 1 mM lysine, EVAPORATION, temperature 298K, pH 7.0
Resolution 2.05 Å R-free 0.253
3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.307
3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.307
3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 2 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.307
3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.307
3TT8 Crystal Structure Analysis of Cu Human Insulin Derivative Deposited 2011-09-14 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；1mM sodium citrate, volume fractions of acetone 10% and 7.5 mM cooper(II) acetate monohydrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP
Resolution 1.12 Å R-free 0.179
3TT8 Crystal Structure Analysis of Cu Human Insulin Derivative Deposited 2011-09-14 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；1mM sodium citrate, volume fractions of acetone 10% and 7.5 mM cooper(II) acetate monohydrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP
Resolution 1.12 Å R-free 0.179
3TT8 Crystal Structure Analysis of Cu Human Insulin Derivative Deposited 2011-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；1mM sodium citrate, volume fractions of acetone 10% and 7.5 mM cooper(II) acetate monohydrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP
Resolution 1.12 Å R-free 0.179
3U4N A novel covalently linked insulin dimer Deposited 2011-10-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：F25C No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1 M Bis-Tris pH 6.5, 3.0 M NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 1.98 Å R-free 0.217
3U4N A novel covalently linked insulin dimer Deposited 2011-10-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：F25C No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1 M Bis-Tris pH 6.5, 3.0 M NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 1.98 Å R-free 0.217
3UTQ Human HLA-A*0201-ALWGPDPAAA Deposited 2011-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 15–24（10 aa） Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M potassium/sodium tartrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
Resolution 1.67 Å R-free 0.244
3UTS 1E6-A*0201-ALWGPDPAAA Complex, Monoclinic Deposited 2011-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain C 15–24（10 aa） Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
Not recorded SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
Resolution 2.71 Å R-free 0.269
3UTS 1E6-A*0201-ALWGPDPAAA Complex, Monoclinic Deposited 2011-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain H 15–24（10 aa） Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
Not recorded SO4 SULFATE ION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
Resolution 2.71 Å R-free 0.269
3UTT 1E6-A*0201-ALWGPDPAAA Complex, Triclinic Deposited 2011-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain C 15–24（10 aa） Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
Resolution 2.60 Å R-free 0.274
3UTT 1E6-A*0201-ALWGPDPAAA Complex, Triclinic Deposited 2011-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain H 15–24（10 aa） Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
Resolution 2.60 Å R-free 0.274
3V19 Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health Deposited 2011-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 IPH PHENOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
Resolution 2.00 Å R-free 0.266
3V1G Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health Deposited 2011-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
Resolution 2.20 Å R-free 0.323
3W11 Insulin receptor ectodomain construct comprising domains L1-CR in complex with human insulin, Alpha-CT peptide(704-719) and FAB 83-7 Deposited 2012-11-06 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SODIUM AZIDE, PH 8.0
Resolution 3.90 Å R-free 0.292
3W12 Insulin receptor ectodomain construct comprising domains L1-CR in complex with high-affinity insulin analogue [D-PRO-B26]-DTI-NH2, alpha-CT peptide(704-719) and FAB 83-7 Deposited 2012-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa） Fragment：UNP residues 25-50
Non-standard monomer：Yes (specific site not provided by mmCIF) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SODIUM AZIDE, PH 8.0
Resolution 4.30 Å R-free 0.349
3W13 Insulin receptor ectodomain construct comprising domains L1-CR in complex with high-affinity insulin analogue [D-PRO-B26]-DTI-NH2, alphact peptide(693-719) and FAB 83-7 Deposited 2012-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa） Fragment：UNP residues 25-50
Non-standard monomer：Yes (specific site not provided by mmCIF) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SOIDUM AZIDE, PH 8.0
Resolution 4.30 Å R-free 0.335
3W7Y 0.92A structure of 2Zn human insulin at 100K Deposited 2013-03-11 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22% DMF(v/v) and 0.08% Zinc chloride(w/v), pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 0.92 Å R-free 0.180
3W7Y 0.92A structure of 2Zn human insulin at 100K Deposited 2013-03-11 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22% DMF(v/v) and 0.08% Zinc chloride(w/v), pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 0.92 Å R-free 0.180
3W7Z 1.15A structure of human 2Zn insulin at 293K Deposited 2013-03-11 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.15 Å R-free 0.195
3W7Z 1.15A structure of human 2Zn insulin at 293K Deposited 2013-03-11 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.15 Å R-free 0.195
3W80 Crystal structure of dodecamer human insulin with double C-axis length of the hexamer 2 Zn insulin cell Deposited 2013-03-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.40 Å R-free 0.248
3W80 Crystal structure of dodecamer human insulin with double C-axis length of the hexamer 2 Zn insulin cell Deposited 2013-03-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa） Fragment：UNP residues 90-110
Chain F 25–54（30 aa） Fragment：UNP residues 25-54
Chain G 90–110（21 aa） Fragment：UNP residues 90-110
Chain H 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.40 Å R-free 0.248
3ZI3 Crystal structure of the B24His-insulin - human analogue Deposited 2013-01-02 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 3；0.075 M LI2SO4, PH 3.0
Resolution 1.70 Å R-free 0.221
3ZQR NMePheB25 insulin analogue crystal structure Deposited 2011-06-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；0.6 M NA2SO4, 0.3 M TRIS PH 8.2, 0.6 M ZN(AC)2, 0.06% PHENOL.
Resolution 1.90 Å R-free 0.281
3ZS2 TyrB25,NMePheB26,LysB28,ProB29-insulin analogue crystal structure Deposited 2011-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 CL CHLORIDE ION × 2 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.2；0.1 M NACITRATE, 0.3 M TRIS PH 8.2, 0.6 MM ZN(AC)2, 0.06% PHENOL
Resolution 1.97 Å R-free 0.252
3ZU1 Structure of LysB29(Nepsilon omega-carboxyheptadecanoyl) des(B30) Human Insulin Deposited 2011-07-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded RCO RESORCINOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；100MM HEPES, 300MM NA-CITRATE, 24% 2-PROPANOL PH 7.5
Resolution 1.60 Å R-free 0.214
4AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'GREEN' SUBSTATE, AVERAGE STRUCTURE Deposited 1998-12-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：ALPHA CHAIN
Chain B 25–54（30 aa） Fragment：BETA CHAIN
Chain C 90–110（21 aa） Fragment：ALPHA CHAIN
Chain D 25–54（30 aa） Fragment：BETA CHAIN
Chain E 90–110（21 aa） Fragment：ALPHA CHAIN
Chain F 25–54（30 aa） Fragment：BETA CHAIN
Chain G 90–110（21 aa） Fragment：ALPHA CHAIN
Chain H 25–54（30 aa） Fragment：BETA CHAIN
Chain I 90–110（21 aa） Fragment：ALPHA CHAIN
Chain J 25–54（30 aa） Fragment：BETA CHAIN
Chain K 90–110（21 aa） Fragment：ALPHA CHAIN
Chain L 25–54（30 aa） Fragment：BETA CHAIN
Not recorded IPH PHENOL × 6 SOLUTION NMR
NMR measurement conditions pH 8；310 K；Pressure 1
NMR sample composition H2O AND D2O
Resolution not provided
4AJX Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa） Fragment：RESIDUES 25-53
Chain C 90–110（21 aa）
Chain D 25–53（29 aa） Fragment：RESIDUES 25-53
Chain E 90–110（21 aa）
Chain F 25–53（29 aa） Fragment：RESIDUES 25-53
Chain G 90–110（21 aa）
Chain H 25–53（29 aa） Fragment：RESIDUES 25-53
Chain I 90–110（21 aa）
Chain J 25–53（29 aa） Fragment：RESIDUES 25-53
Chain K 90–110（21 aa）
Chain L 25–53（29 aa） Fragment：RESIDUES 25-53
Not recorded 16E N-(16-Carboxyhexadecanoyl)-L-glutamic acid × 2 RCO RESORCINOL × 6 NA SODIUM ION × 2 IMD IMIDAZOLE × 3 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；0.6 M IMIDAZOLE/MALONIC ACID PH 7.0
Resolution 1.20 Å R-free 0.160
4AJZ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa） Fragment：DELTA B30, RESIDUES 25-53
Not recorded ZN ZINC ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions MICROBATCH；pH 7.5；MICROBATCH METHOD 5MM PHENOL, 0.4M NACL; 6% (V/V) ETHANOL, 100MM HEPES PH 7.5
Resolution 1.80 Å R-free 0.255
4AJZ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa） Fragment：DELTA B30, RESIDUES 25-53
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 3 IPH PHENOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions MICROBATCH；pH 7.5；MICROBATCH METHOD 5MM PHENOL, 0.4M NACL; 6% (V/V) ETHANOL, 100MM HEPES PH 7.5
Resolution 1.80 Å R-free 0.255
4AK0 Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa） Fragment：DELTA B30, RESIDUES 25-53
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.8；pH 7.8
Resolution 2.28 Å R-free 0.232
4AKJ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-23 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded IPH PHENOL × 3 16E N-(16-Carboxyhexadecanoyl)-L-glutamic acid × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.01 Å R-free 0.229
4AKJ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-23 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.01 Å R-free 0.229
4CXL Human insulin analogue (D-ProB8)-insulin Deposited 2014-04-07 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 SODIUM CITRATE, 40% V/V MPD, PROTEIN CONCENTRATION 5MG/ML IN 20 MM HCL
Resolution 1.50 Å R-free 0.197
4CXL Human insulin analogue (D-ProB8)-insulin Deposited 2014-04-07 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 SODIUM CITRATE, 40% V/V MPD, PROTEIN CONCENTRATION 5MG/ML IN 20 MM HCL
Resolution 1.50 Å R-free 0.197
4CXN Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form I Deposited 2014-04-07 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 M SODIUM CITRATE, 40% V/V MPD, PROTEIN IN 20 MM HCL AT 7 MG/ML
Resolution 1.70 Å R-free 0.209
4CXN Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form I Deposited 2014-04-07 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 M SODIUM CITRATE, 40% V/V MPD, PROTEIN IN 20 MM HCL AT 7 MG/ML
Resolution 1.70 Å R-free 0.209
4CY7 Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form II Deposited 2014-04-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 ACT ACETATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.0375 M NA2SO4, PH 4.0
Resolution 1.40 Å R-free 0.199
4CY7 Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form II Deposited 2014-04-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 ACT ACETATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.0375 M NA2SO4, PH 4.0
Resolution 1.40 Å R-free 0.199
4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 90–110（21 aa）
Mutation：A10C, B4C No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 1.98 Å R-free 0.278
4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 25–52（28 aa）
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 1.98 Å R-free 0.278
4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 90–110（21 aa）
Mutation：A10C, B4C No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 1.98 Å R-free 0.278
4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 25–52（28 aa）
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 1.98 Å R-free 0.278
4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–52（28 aa）
Chain C 90–110（21 aa）
Chain D 25–52（28 aa）
Mutation：A10C, B4C Mutation：A10C, B4C ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
Resolution 1.98 Å R-free 0.278
4EWW Human Insulin Deposited 2012-04-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000, cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.30 Å R-free 0.287
4EWX Human Insulin Deposited 2012-04-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000, cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.20 Å R-free 0.240
4EWZ Human Insulin Deposited 2012-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Betalin H, lot # 310996-1), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.79 Å R-free 0.269
4EX0 Human Insulin Deposited 2012-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Betalin H, lot # 310996-1), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.86 Å R-free 0.226
4EX1 Human Insulin Deposited 2012-04-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Betalin H, lot # 310996-1), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.66 Å R-free 0.239
4EXX Human Insulin Deposited 2012-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.55 Å R-free 0.263
4EY1 Human Insulin Deposited 2012-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.47 Å R-free 0.219
4EY9 Human Insulin Deposited 2012-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.47 Å R-free 0.255
4EYD Human Insulin Deposited 2012-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.47 Å R-free 0.223
4EYN Human Insulin Deposited 2012-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.53 Å R-free 0.271
4EYP Human Insulin Deposited 2012-05-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.59 Å R-free 0.223
4F0N Human Insulin Deposited 2012-05-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # XS60393), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.68 Å R-free 0.264
4F0O Human Insulin Deposited 2012-05-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium citrate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # XS60393), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.67 Å R-free 0.221
4F1A Human Insulin Deposited 2012-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # XS60393), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.80 Å R-free 0.213
4F1B Human Insulin Deposited 2012-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # TS 62987), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.59 Å R-free 0.227
4F1C Human Insulin Deposited 2012-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # TS 62987), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.70 Å R-free 0.225
4F1D Human Insulin Deposited 2012-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.64 Å R-free 0.219
4F1F Human Insulin Deposited 2012-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 560347), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.68 Å R-free 0.258
4F1G Human insulin Deposited 2012-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 560347), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.64 Å R-free 0.222
4F4T Human Insulin Deposited 2012-05-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.64 Å R-free 0.214
4F4V Human Insulin Deposited 2012-05-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.64 Å R-free 0.264
4F51 Human Insulin Deposited 2012-05-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.64 Å R-free 0.212
4F8F Human Insulin Deposited 2012-05-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 405936), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.68 Å R-free 0.198
4FG3 Crystal Structure Analysis of the Human Insulin Deposited 2012-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；Hanging drop: 2 uL 0.1 M sodium phosphate, 10% w/v PEG 6K + 2 uL Human Insulin 100 U/mL (Humulin R, lot #A 405936). Cryo = mother liquor + 10% glycerol, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.252
4FKA High resolution structure of the manganese derivative of insulin Deposited 2012-06-13 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded NA SODIUM ION × 1 MN MANGANESE (II) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；The protein solution consisted of 7.5 mg mL-1 of zinc-free insulin in 0.02 mol L-1 hydrochloric acid. The reservoir solution was at pH 6.4 containing 1mM sodium citrate, volume fraction of aceton 10 % ,9 mmol L-1 manganese(II) sulphate monohydrate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.08 Å R-free 0.194
4FKA High resolution structure of the manganese derivative of insulin Deposited 2012-06-13 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded MN MANGANESE (II) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；The protein solution consisted of 7.5 mg mL-1 of zinc-free insulin in 0.02 mol L-1 hydrochloric acid. The reservoir solution was at pH 6.4 containing 1mM sodium citrate, volume fraction of aceton 10 % ,9 mmol L-1 manganese(II) sulphate monohydrate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.08 Å R-free 0.194
4FKA High resolution structure of the manganese derivative of insulin Deposited 2012-06-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded NA SODIUM ION × 3 MN MANGANESE (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；The protein solution consisted of 7.5 mg mL-1 of zinc-free insulin in 0.02 mol L-1 hydrochloric acid. The reservoir solution was at pH 6.4 containing 1mM sodium citrate, volume fraction of aceton 10 % ,9 mmol L-1 manganese(II) sulphate monohydrate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.08 Å R-free 0.194
4GBC Crystal structure of aspart insulin at pH 6.5 Deposited 2012-07-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 uL mother liquor (0.1 M MES monohydrate, pH 6.5, 1.6 M magnesium sulfate heptahydrate) + 2 uL protein (aspart insulin, 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.78 Å R-free 0.224
4GBI Crystal structure of aspart insulin at pH 6.5 Deposited 2012-07-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 uL mother liquor (0.1 M MES, pH 6.5, 1.6 M magnesium sulfate heptahydrate) + 2 uL protein (aspart insulin, 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.202
4GBK Crystal structure of aspart insulin at pH 8.5 Deposited 2012-07-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；2 uL mother liquor (0.1 M Tris, pH 8.5, 1.5 M ammonium sulfate, 12% v/v glycerol) + 2 uL protein (aspart insulin 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.40 Å R-free 0.266
4GBL Crystal structure of aspart insulin at pH 8.5 Deposited 2012-07-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；2 uL mother liquor (0.1 M Tris, pH 8.5, 1.5 M ammonium sulfate, 12% v/v glycerol) + 2 uL protein (aspart insulin 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.50 Å R-free 0.262
4GBN Crystal structure of aspart insulin at pH 6.5 Deposited 2012-07-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 uL mother liquor (0.1 M MES monohydrate, pH 6.5, 1.6 M magnesium sulfate heptahydrate) + 2 uL protein (aspart insulin, 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.87 Å R-free 0.214
4IUZ High resolution crystal structure of racemic ester insulin Deposited 2013-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-64
Mutation：H34D,P52K,K53P PEG DI(HYDROXYETHYL)ETHER × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 3.6；292 K；5 mg/mL protein, 0.05 M citric acid, 38% v/v PEG200, pH 3.6, VAPOR DIFFUSION, HANGING DROP, temperature 292K
Resolution 1.60 Å R-free 0.249
4IYD Insulin glargine crystal structure 1 Deposited 2013-01-28 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 30% PEG-400 v/v, 0.2 M sodium citrate dihydrate, pH 8.0, vapor diffusion, sitting drop, temperature 293K
Resolution 1.66 Å R-free 0.225
4IYF Insulin glargine crystal structure 2 Deposited 2013-01-28 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 30% PEG-400 v/v, 0.2 M sodium citrate dihydrate, pH 8.0, vapor diffusion, sitting drop, temperature 293K
Resolution 1.80 Å R-free 0.242
4NIB Crystal structure of human insulin mutant B20 D-ala, B23 D-ala Deposited 2013-11-05 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：G20(DAL), G23(DAL) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；These insulin crystals were obtained from a co-crystallization experiment with insulin receptor fragment IR310.T. Crystals were formed in the presence of IR310.T as detailed for the IR310.T complex with native human insulin - in Menting et al. 2013, Nature 493:241-245. Crystallant was 0.7 M trisodium citrate, 0.1 M imidazole-HCl pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 294K
Resolution 1.40 Å R-free 0.163
4OGA Insulin in complex with Site 1 of the human insulin receptor Deposited 2014-01-15 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SODIUM AZIDE, PH 8.0 , VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.50 Å R-free 0.284
4P65 Crystal structure of an cyclohexylalanine substituted insulin analog. Deposited 2014-03-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Chain E 90–110（21 aa） Fragment：UNP residues 90-110
Chain F 25–54（30 aa） Fragment：UNP residues 25-54
Chain G 90–110（21 aa） Fragment：UNP residues 90-110
Chain H 25–54（30 aa） Fragment：UNP residues 25-54
Chain I 90–110（21 aa） Fragment：UNP residues 90-110
Chain J 25–54（30 aa） Fragment：UNP residues 25-54
Chain K 90–110（21 aa） Fragment：UNP residues 90-110
Chain L 25–54（30 aa） Fragment：UNP residues 25-54
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；277 K；sodium citrate, phenol, sodium chloride, zinc acetate, tris
Resolution 1.50 Å R-free 0.203
4RXW Crystal Structure of the cobalt human insulin derivative Deposited 2014-12-12 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded CO COBALT (II) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；the protein solution consisted 7.5 mg mL-1 Zn-free insulin in 0.02 M HCl, while the reservoir solution contained 1 mM solution of sodium citrate, pH 6.4, (acetone) = 10 %, 16,5 mM solution of cobalt(II) acetate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.73 Å R-free 0.206
4RXW Crystal Structure of the cobalt human insulin derivative Deposited 2014-12-12 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded CO COBALT (II) ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；the protein solution consisted 7.5 mg mL-1 Zn-free insulin in 0.02 M HCl, while the reservoir solution contained 1 mM solution of sodium citrate, pH 6.4, (acetone) = 10 %, 16,5 mM solution of cobalt(II) acetate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.73 Å R-free 0.206
4RXW Crystal Structure of the cobalt human insulin derivative Deposited 2014-12-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded CO COBALT (II) ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；the protein solution consisted 7.5 mg mL-1 Zn-free insulin in 0.02 M HCl, while the reservoir solution contained 1 mM solution of sodium citrate, pH 6.4, (acetone) = 10 %, 16,5 mM solution of cobalt(II) acetate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.73 Å R-free 0.206
4UNE Human insulin B26Phe mutant crystal structure Deposited 2014-05-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.15 M NA2SO4, PH 4.0, CP 5 MG/ML
Resolution 1.59 Å R-free 0.180
4UNE Human insulin B26Phe mutant crystal structure Deposited 2014-05-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：YES SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.15 M NA2SO4, PH 4.0, CP 5 MG/ML
Resolution 1.59 Å R-free 0.180
4UNE Human insulin B26Phe mutant crystal structure Deposited 2014-05-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：YES Mutation：YES SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.15 M NA2SO4, PH 4.0, CP 5 MG/ML
Resolution 1.59 Å R-free 0.180
4UNG Human insulin B26Asn mutant crystal structure Deposited 2014-05-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.035 M (NH4)2SO4, PH 4.0, CP = 5 MG/ML
Resolution 1.81 Å R-free 0.220
4UNG Human insulin B26Asn mutant crystal structure Deposited 2014-05-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：YES SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.035 M (NH4)2SO4, PH 4.0, CP = 5 MG/ML
Resolution 1.81 Å R-free 0.220
4UNH Human insulin B26Gly mutant crystal structure Deposited 2014-05-28 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：YES SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4；0.08 M NA2SO4, PH 4.0, CP = 5 MG/ML
Resolution 2.75 Å R-free 0.355
4WDI Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2014-09-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 39–47（9 aa）
Not recorded EDO 1,2-ETHANEDIOL × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；20% PEG 3350, 0.2 M Sodium malonate, and 0.1 M Bis-Tris Propane, pH 6.5
Resolution 2.31 Å R-free 0.283
4WDI Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2014-09-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain F 39–47（9 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；20% PEG 3350, 0.2 M Sodium malonate, and 0.1 M Bis-Tris Propane, pH 6.5
Resolution 2.31 Å R-free 0.283
4XC4 Insulin co-crystallizes in the presence of it beta-cell chaperone sulfatide Deposited 2014-12-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.3M MAGNESIUM SULFATE, 0.1M MES
Resolution 1.50 Å R-free 0.254
4Y19 immune complex Deposited 2015-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric
Chain C 75–90（16 aa） Fragment：UNP residues 75-90
Not recorded MLI MALONATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；100 mM MES pH 6.0, 2 M ammonium sulfate and 0.2 M sodium malonate
Resolution 2.50 Å R-free 0.196
4Y1A immune complex Deposited 2015-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric
Chain C 75–90（16 aa） Fragment：UNP residues 75-90
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；BisTris, ammonium sulfate and pentaerythritol ethoxylate (3/4 EO/OH)
Resolution 4.00 Å R-free 0.283
4Z76 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 39–47（9 aa） Fragment：UNP residues 39-47
Not recorded EDO 1,2-ETHANEDIOL × 5 GOL GLYCEROL × 2 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；291 K；G9V crystals were grown in 20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
Resolution 1.88 Å R-free 0.230
4Z76 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain F 39–47（9 aa） Fragment：UNP residues 39-47
Not recorded EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 11 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；291 K；G9V crystals were grown in 20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
Resolution 1.88 Å R-free 0.230
4Z77 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 39–47（9 aa） Fragment：UNP residues 39-47
Not recorded GOL GLYCEROL × 4 15P POLYETHYLENE GLYCOL (N=34) × 1 EDO 1,2-ETHANEDIOL × 7 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；291 K；20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
Resolution 1.85 Å R-free 0.253
4Z77 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain F 39–47（9 aa） Fragment：UNP residues 39-47
Not recorded GOL GLYCEROL × 3 15P POLYETHYLENE GLYCOL (N=34) × 2 EDO 1,2-ETHANEDIOL × 5 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；291 K；20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
Resolution 1.85 Å R-free 0.253
4Z78 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 39–48（10 aa） Fragment：UNP residues 39-48
Not recorded EDO 1,2-ETHANEDIOL × 3 GOL GLYCEROL × 2 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
Resolution 2.30 Å R-free 0.233
4Z78 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain F 39–48（10 aa） Fragment：UNP residues 39-48
Not recorded EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
Resolution 2.30 Å R-free 0.233
4Z78 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain I 39–48（10 aa） Fragment：UNP residues 39-48
Not recorded EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
Resolution 2.30 Å R-free 0.233
5AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'RED' SUBSTATE, AVERAGE STRUCTURE Deposited 1998-12-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：ALPHA CHAIN
Chain B 25–54（30 aa） Fragment：BETA CHAIN
Chain C 90–110（21 aa） Fragment：ALPHA CHAIN
Chain D 25–54（30 aa） Fragment：BETA CHAIN
Chain E 90–110（21 aa） Fragment：ALPHA CHAIN
Chain F 25–54（30 aa） Fragment：BETA CHAIN
Chain G 90–110（21 aa） Fragment：ALPHA CHAIN
Chain H 25–54（30 aa） Fragment：BETA CHAIN
Chain I 90–110（21 aa） Fragment：ALPHA CHAIN
Chain J 25–54（30 aa） Fragment：BETA CHAIN
Chain K 90–110（21 aa） Fragment：ALPHA CHAIN
Chain L 25–54（30 aa） Fragment：BETA CHAIN
Not recorded IPH PHENOL × 6 SOLUTION NMR
NMR measurement conditions pH 8；310 K；Pressure 1
NMR sample composition H2O AND D2O
Resolution not provided
5BOQ Human insulin with intra-chain chemical crosslink between modified B24 and B29 Deposited 2015-05-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: Tetrameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain E 90–110（21 aa） Fragment：UNP residues 90-110
Chain F 25–54（30 aa） Fragment：UNP residues 25-54
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 3；293 K；0.1 M (NH4)2SO4, 1% (v/v) dioxane
Resolution 1.70 Å R-free 0.232
5BOQ Human insulin with intra-chain chemical crosslink between modified B24 and B29 Deposited 2015-05-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: Tetrameric
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Chain G 90–110（21 aa） Fragment：UNP residues 90-110
Chain H 25–54（30 aa） Fragment：UNP residues 25-54
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 3；293 K；0.1 M (NH4)2SO4, 1% (v/v) dioxane
Resolution 1.70 Å R-free 0.232
5BPO Human insulin with intra-chain chemical crosslink between modified B27 and B29 Deposited 2015-05-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 3；293 K；0.05 M Li2SO4
Resolution 1.90 Å R-free 0.304
5BQQ Human insulin with intra-chain chemical crosslink between modified B27 and B30 Deposited 2015-05-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–52（28 aa）
Chain C 90–110（21 aa）
Chain D 25–52（28 aa）
Chain E 90–110（21 aa）
Chain F 25–52（28 aa）
Chain G 90–110（21 aa）
Chain H 25–52（28 aa）
Chain I 90–110（21 aa）
Chain J 25–52（28 aa）
Chain K 90–110（21 aa）
Chain L 25–52（28 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 10 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.6 M Na2SO4, 0.3 M Tris pH 7.5, 0.6 mM Zn(Ac)2, 0.06% (w/v) phenol
Resolution 1.54 Å R-free 0.195
5BTS Structural and biophysical characterization of a covalent insulin dimer formed during storage of neutral formulation of human insulin Deposited 2015-06-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.2 M Ammonium sulfate, 0.1 M Hepes, 25% w/v PEG3350
Resolution 1.77 Å R-free 0.206
5CJO Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2015-07-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain a 90–109（20 aa）
Not recorded EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；6% v/v Tacsimate pH 7.0, 0.1 M HEPES pH 7.0, 8% w/v Polyethylene glycol monomethyl ether 5,000, and 8% v/v tert-butanol as additive.
Resolution 3.29 Å R-free 0.245
5CNY Crystal Structure of human zinc insulin at pH 5.5 Deposited 2015-07-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 mcL protein (6 mg/mL) + 2 mcL well (0.1 M Na2HPO4 pH 5.5, 10 % m/v PEG 6,000)
Resolution 1.70 Å R-free 0.213
5CO2 Crystalization of human zinc insulin at pH 5.5 Deposited 2015-07-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2 mcL protein (6 mg/mL in 2 mM HCl) + 2 mcL well solution (0.1 M Na2HPO4 pH 5.5, 10 % m/v PEG 6,000)
Resolution 1.70 Å R-free 0.217
5CO6 Crystal structure of human zinc insulin at pH 6.5 Deposited 2015-07-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 MG MAGNESIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 mcL protein (6 mg/mL) + 2 mcL well 0.1 M MES buffer pH 6.5, 1.6 M MgSO4 (directly from the commercially available kit Hampton Crystal Screen II, formulation 20)
Resolution 1.80 Å R-free 0.226
5CO9 Crystal structure of human zinc insulin at pH 6.5 Deposited 2015-07-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Chain C 90–110（21 aa） Fragment：UNP residues 90-110
Chain D 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 mcL protein (6 mg/mL) + 2 mcL well (0.1 M MES buffer pH 6.5, 1.6 M MgSO4, directly from the commercially available kit Hampton Crystal Screen II, formulation #20)
Resolution 1.92 Å R-free 0.237
5E7W X-ray Structure of Human Recombinant 2Zn insulin at 0.92 Angstrom Deposited 2015-10-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 ACT ACETATE ION × 3 POL N-PROPANOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 6.3；293 K；The crystals were prepared by a batch method similar to that of Baker et al, 1988 [1], modified as follows: 0.01g of insulin as a fine powder was placed in a clean test tube; 0.02M HCl was added to dissolve the protein; on addition of 0.15 mL of 0.15 M zinc acetate the solution became cloudy due to precipitation of the protein; 0.3 mL of acetone and then 0.5 mL of trisodium citrate together with 0.8 mL of water were added and the solution went clear; the pH was checked and increased with NaOH to a pH between 8 and 9 for different batches, thus ensuring complete dissolution. It was then adjusted to the required value of pH 6.3. If any slight turbidity occurred, it was removed by warming the solution. The solution was then filtered using a Millipore membrane/acetate cellulose acetate filter. This removes any nuclei which will encourage precipitation or formation of masses of small crystals. The solution was then warmed to 50 deg C by surrounding the test tube with preheated water in a Dewar. This allowed the solution to cool slowly to room temperature. The test tube was lightly sealed with cling film; crystals formed within a few days and were of suitable size for X-ray diffraction within two weeks; the test tube containing crystals was kept at 4 degC prior to data collection. The crystal used for data collection was about 0.2 mm3.
Resolution 0.95 Å R-free 0.144
5EMS Crystal Structure of an iodinated insulin analog Deposited 2015-11-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.1 M sodium citrate, 0.08% zinc acetate, 2% phenol
Resolution 2.30 Å R-free 0.233
5EN9 High resolution x-ray crystal structure of isotope-labeled ester-insulin Deposited 2015-11-09 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 13% MPD
Resolution 1.50 Å R-free 0.177
5EN9 High resolution x-ray crystal structure of isotope-labeled ester-insulin Deposited 2015-11-09 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 13% MPD
Resolution 1.50 Å R-free 0.177
5ENA Xray crystal structure of isotope-labeled human insulin Deposited 2015-11-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：1-(13C=18O)PheB24 No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 11% MPD
Resolution 1.35 Å R-free 0.164
5ENA Xray crystal structure of isotope-labeled human insulin Deposited 2015-11-09 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：1-(13C=18O)PheB24 No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 11% MPD
Resolution 1.35 Å R-free 0.164
5HPR Insulin with proline analog HyP at position B28 in the T2 state Deposited 2016-01-21 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：Pro28Hyp Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 2 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 0.5 mM zinc acetate, 8.5% acetone, 0.5 M sodium citrate
Resolution 1.33 Å R-free 0.164
5HPR Insulin with proline analog HyP at position B28 in the T2 state Deposited 2016-01-21 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：Pro28Hyp Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 3 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 0.5 mM zinc acetate, 8.5% acetone, 0.5 M sodium citrate
Resolution 1.33 Å R-free 0.164
5HPU Insulin with proline analog HyP at position B28 in the R6 state Deposited 2016-01-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 17 mM zinc acetate, 1% phenol, 1.95 M sodium citrate
Resolution 2.20 Å R-free 0.218
5HQI Insulin with proline analog HzP at position B28 in the T2 state Deposited 2016-01-21 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：Pro28HzP Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.25；295 K；462.5 mM sodium citrate, 100 mM HEPES
Resolution 0.97 Å R-free 0.158
5HRQ Insulin with proline analog HzP at position B28 in the R6 state Deposited 2016-01-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 17 mM zinc acetate, 1% phenol, 7.5% acetone, 2.675 M sodium citrate
Resolution 1.28 Å R-free 0.168
5MAM Human insulin in complex with serotonin Deposited 2016-11-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 SRO SEROTONIN × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
Resolution 2.20 Å R-free 0.280
5MAM Human insulin in complex with serotonin Deposited 2016-11-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 SRO SEROTONIN × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
Resolution 2.20 Å R-free 0.280
5MAM Human insulin in complex with serotonin Deposited 2016-11-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain 0 90–110（21 aa）
Chain 1 25–54（30 aa）
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Chain W 90–110（21 aa）
Chain X 25–54（30 aa）
Chain Y 90–110（21 aa）
Chain Z 25–54（30 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 SRO SEROTONIN × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
Resolution 2.20 Å R-free 0.280
5MAM Human insulin in complex with serotonin Deposited 2016-11-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain 2 90–110（21 aa）
Chain 3 25–54（30 aa）
Chain 4 90–110（21 aa）
Chain 5 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 SRO SEROTONIN × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
Resolution 2.20 Å R-free 0.280
5MHD Biosynthetic engineered A22S-B3K-B31R human insulin monomer structure in water/acetonitrile solutions. Deposited 2016-11-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa） Fragment：chain A
Chain B 25–55（31 aa） Fragment：chain B
Mutation：22S No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 2.5；298 K；Ionic strength (raw mmCIF value) 1；Pressure ambient
NMR sample composition 2.5 mM None Insulin, 73 % None H2O, 27 % 2H CD3CN, H2O / CD3CN | H2O / CD3CN
NMR sample composition 2.5 mM None Insulin, 73 % 2H D2O, 27 % 2H CD3CN, D2O / CD3CN | D2O / CD3CN
Resolution not provided
5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 ARG ARGININE × 3 SRO SEROTONIN × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
Resolution 2.02 Å R-free 0.310
5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Not recorded ZN ZINC ION × 3 CL CHLORIDE ION × 2 ARG ARGININE × 3 SRO SEROTONIN × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
Resolution 2.02 Å R-free 0.310
5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Chain W 90–110（21 aa）
Chain X 25–54（30 aa）
Chain Y 90–110（21 aa）
Chain Z 25–54（30 aa）
Chain a 90–110（21 aa）
Chain b 25–54（30 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 SRO SEROTONIN × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
Resolution 2.02 Å R-free 0.310
5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain c 90–110（21 aa）
Chain d 25–54（30 aa）
Chain e 90–110（21 aa）
Chain f 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 3 SRO SEROTONIN × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
Resolution 2.02 Å R-free 0.310
5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 ARG ARGININE × 3 SRO SEROTONIN × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
Resolution 1.88 Å R-free 0.269
5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 ARG ARGININE × 3 SRO SEROTONIN × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
Resolution 1.88 Å R-free 0.269
5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Chain W 90–110（21 aa）
Chain X 25–54（30 aa）
Chain Y 90–110（21 aa）
Chain Z 25–54（30 aa）
Chain a 90–110（21 aa）
Chain b 25–54（30 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 SRO SEROTONIN × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
Resolution 1.88 Å R-free 0.269
5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain c 90–110（21 aa）
Chain d 25–54（30 aa）
Chain e 90–110（21 aa）
Chain f 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 SRO SEROTONIN × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
Resolution 1.88 Å R-free 0.269
5MWQ Biosynthetic engineered A21K-B31K-B32R human insulin monomer structure in water/acetonitrile solution Deposited 2017-01-19 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–56（32 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 2.5；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition 2.5 mM insulin, 73% H2O/27% CD3CN | 73% H2O/27% CD3CN
NMR sample composition 2.5 mM insulin, 73% D2O/27% CD3CN | 73% D2O/27% CD3CN
Resolution not provided
5T7R A6-A11 trans-dicarba human insulin Deposited 2016-09-05 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：C6(ABA), C11(ABA) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；300 K；0.9 M potassium sodium tartrate, 0.1 M Tris HCl pH 8.5, 0.5% PEG 5000 MME
Resolution 1.55 Å R-free 0.217
5T7R A6-A11 trans-dicarba human insulin Deposited 2016-09-05 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：C6(ABA), C11(ABA) Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；300 K；0.9 M potassium sodium tartrate, 0.1 M Tris HCl pH 8.5, 0.5% PEG 5000 MME
Resolution 1.55 Å R-free 0.217
5UDP High resolution x-ray crystal structure of synthetic insulin lispro Deposited 2016-12-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain D 25–54（30 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain I 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.2；292 K；0.3 M TRIS, 0.5 M sodium sulfate, 0.6 mM Zinc acetate, 0.06% phenol
Resolution 1.35 Å R-free 0.194
5UDP High resolution x-ray crystal structure of synthetic insulin lispro Deposited 2016-12-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain E 90–110（21 aa）
Chain H 25–54（30 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 1 CL CHLORIDE ION × 1 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.2；292 K；0.3 M TRIS, 0.5 M sodium sulfate, 0.6 mM Zinc acetate, 0.06% phenol
Resolution 1.35 Å R-free 0.194
5UOZ Insulin with proline analog FyP at position B28 in the T2 state Deposited 2017-02-01 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；293 K；0.3M Tris, 0.5mM Zinc Acetate, 425mM Sodium Citrate
Resolution 1.17 Å R-free 0.155
5UQA Insulin with proline analog FzP at position B28 in the R6 state Deposited 2017-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 6 GOL GLYCEROL × 1 ACN ACETONE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.3M Tris pH8, 17mM Zinc Acetate, 1% Phenol, 0.3875M Sodium Citrate, 2.1% Acetone
Resolution 1.31 Å R-free 0.182
5URT Insulin with proline analog DhP at position B28 in the T2 state Deposited 2017-02-12 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；200mM Sodium Citrate, 100mM Hepes pH 7.75
Resolution 1.18 Å R-free 0.142
5URT Insulin with proline analog DhP at position B28 in the T2 state Deposited 2017-02-12 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；200mM Sodium Citrate, 100mM Hepes pH 7.75
Resolution 1.18 Å R-free 0.142
5URU Insulin with proline analog DhP at position B28 in the R6 state Deposited 2017-02-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% Phenol, 313mM Sodium Citrate, 11.25% Acetone
Resolution 2.41 Å R-free 0.246
5URU Insulin with proline analog DhP at position B28 in the R6 state Deposited 2017-02-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% Phenol, 313mM Sodium Citrate, 11.25% Acetone
Resolution 2.41 Å R-free 0.246
5USP Insulin with proline analog Pip at position B28 in the T2 state Deposited 2017-02-13 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；275mM Sodium Citrate, 100mM Hepes pH 8.0
Resolution 1.17 Å R-free 0.153
5USP Insulin with proline analog Pip at position B28 in the T2 state Deposited 2017-02-13 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；275mM Sodium Citrate, 100mM Hepes pH 8.0
Resolution 1.17 Å R-free 0.153
5USS Insulin with proline analog PiP at position B28 in the R6 state Deposited 2017-02-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% phenol, 313mM Sodium Citrate, 11.25% Acetone
Resolution 2.06 Å R-free 0.225
5USV Insulin with proline analog AzeP at position B28 in the T2 state Deposited 2017-02-14 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；238mM Sodium citrate, 100mM Hepes pH 7.75
Resolution 1.30 Å R-free 0.159
5USV Insulin with proline analog AzeP at position B28 in the T2 state Deposited 2017-02-14 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；238mM Sodium citrate, 100mM Hepes pH 7.75
Resolution 1.30 Å R-free 0.159
5UU2 Insulin with proline analog ThioP at position B28 in the T2 state Deposited 2017-02-15 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；238mM Sodium Citrate, 100mM Hepes pH 8.5
Resolution 1.22 Å R-free 0.156
5UU2 Insulin with proline analog ThioP at position B28 in the T2 state Deposited 2017-02-15 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；238mM Sodium Citrate, 100mM Hepes pH 8.5
Resolution 1.22 Å R-free 0.156
5UU3 Insulin with proline analog DfP at position B28 in the R6 state Deposited 2017-02-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% phenol, 425mM Sodium Citrate, 15% Acetone
Resolution 2.25 Å R-free 0.292
5UU3 Insulin with proline analog DfP at position B28 in the R6 state Deposited 2017-02-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Chain W 90–110（21 aa）
Chain X 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 5 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% phenol, 425mM Sodium Citrate, 15% Acetone
Resolution 2.25 Å R-free 0.292
5UU4 Insulin with proline analog ThioP at position B28 in the R6 state Deposited 2017-02-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% Phenol, 275mM Sodium Citrate, 9.38% Acetone
Resolution 1.97 Å R-free 0.264
5VIZ X-Ray structure of Insulin Glargine Deposited 2017-04-17 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；291 K；Microbatch
Resolution 1.70 Å R-free 0.183
5WBT Solution Structure and Dynamics of an Ultra-Stable Single-Chain Insulin Analog STUDIES OF AN ENGINEERED MONOMER AND IMPLICATIONS FOR RECEPTOR BINDING Deposited 2017-06-29 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 25–54（30 aa） Fragment：residues 25-110
Chain A 90–110（21 aa） Fragment：residues 25-110
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7.4；298 K；Ionic strength (raw mmCIF value) 0；Pressure 1
NMR sample composition 1 mM [U-13C; U-15N] Single chain insulin SCI-b, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain a 90–109（20 aa）
Chain b 90–109（20 aa）
Not recorded ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
Resolution 3.95 Å R-free 0.291
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain c 90–109（20 aa）
Chain d 90–109（20 aa）
Not recorded ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
Resolution 3.95 Å R-free 0.291
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain e 90–109（20 aa）
Chain f 90–109（20 aa）
Not recorded ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
Resolution 3.95 Å R-free 0.291
5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain g 90–109（20 aa）
Chain h 90–109（20 aa）
Not recorded ZN ZINC ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
Resolution 3.95 Å R-free 0.291
6B3Q Cryo-EM structure of human insulin degrading enzyme in complex with insulin Deposited 2017-09-22 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain a 1–110（110 aa）
Chain b 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE；The cryo grids were made using Spotiton and homemade plunger
Resolution 3.70 Å
6B70 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain and insulin Deposited 2017-10-03 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain a 1–110（110 aa）
Chain c 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE；The cryo grids were made using Spotiton and homemade plunger
Resolution 3.70 Å
6BFC Cryo-EM structure of human insulin degrading enzyme in complex with insulin Deposited 2017-10-26 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain a 1–110（110 aa）
Chain b 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE；Grids made using Spotiton
Resolution 3.70 Å
6CE7 Insulin Receptor ectodomain in complex with one insulin molecule Deposited 2018-02-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain N 90–110（21 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5；Hepes Saline (HBS)
cryo-EM vitrification conditions Cryogen ETHANE；Grids made with SpotItOn
Resolution 7.40 Å
6CE9 Insulin Receptor ectodomain in complex with two insulin molecules Deposited 2018-02-11 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric
Chain K 90–110（21 aa）
Chain N 90–110（21 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5；Hepes Saline (HBS)
cryo-EM vitrification conditions Cryogen ETHANE；Grids made with SpotItOn
Resolution 4.30 Å
6CEB Insulin Receptor ectodomain in complex with two insulin molecules - C1 symmetry Deposited 2018-02-11 Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric
Chain K 90–110（21 aa）
Chain N 90–110（21 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5；Hepes Saline (HBS)
cryo-EM vitrification conditions Cryogen ETHANE；Grids made with SpotItOn
Resolution 4.70 Å
6CK2 Insulin analog containing a YB26W mutation Deposited 2018-02-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；Crystals were obtained by hanging-drop vapor diffusion at room temperature in the presence of a 1:1.7 ratio of Zn2+ to protein monomer and a 3.5:1 ratio of phenol to protein monomer in Tris-HCl
Resolution 2.25 Å R-free 0.247
6GNQ Monoclinic crystalline form of human insulin, complexed with meta-cresol Deposited 2018-05-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded CRS M-CRESOL × 6 EDO 1,2-ETHANEDIOL × 6 ZN ZINC ION × 2 IS8 isothiocyanate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 6.1；298 K；sodium-monopotassium phosphate buffer, zinc acetate, m-cresol
Resolution 2.20 Å R-free 0.279
6GNQ Monoclinic crystalline form of human insulin, complexed with meta-cresol Deposited 2018-05-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Chain W 90–110（21 aa）
Chain X 25–54（30 aa）
Not recorded CRS M-CRESOL × 6 EDO 1,2-ETHANEDIOL × 4 ZN ZINC ION × 2 IS8 isothiocyanate × 2 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 6.1；298 K；sodium-monopotassium phosphate buffer, zinc acetate, m-cresol
Resolution 2.20 Å R-free 0.279
6GV0 Insulin glulisine Deposited 2018-06-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain B 25–54（30 aa）
Chain D 25–54（30 aa）
Chain G 90–110（21 aa）
Chain I 90–110（21 aa）
Not recorded ZN ZINC ION × 6 FMT FORMIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；0.2-0.4M Mg-formate 0.1M BisTris buffer
Resolution 1.26 Å R-free 0.152
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain J 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain B 25–54（30 aa）
Chain E 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain F 25–54（30 aa）
Chain K 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain I 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 7 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain N 90–110（21 aa）
Chain Q 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 8 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain P 25–54（30 aa）
Chain R 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
Resolution 1.82 Å R-free 0.229
6HN5 Leucine-zippered human insulin receptor ectodomain with single bound insulin - "upper" membrane-distal part Deposited 2018-09-14 Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.20 Å
6JK8 Cryo-EM structure of the full-length human IGF-1R in complex with insulin Deposited 2019-02-27 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4；PBS with detergent
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 5.00 Å
6JR3 Crystal structure of insulin hexamer fitted into cryo EM density map where each dimer was kept as rigid body Deposited 2019-04-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 14.50 Å
6NWV Insulin Lispro Analog Deposited 2019-02-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P CRS M-CRESOL × 7 ZN ZINC ION × 2 GOL GLYCEROL × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.1 M HEPES sodium pH 7.5; 0.4 M Potassium sodium tartrate tetrahydrate.
Resolution 1.60 Å R-free 0.257
6O17 Recombinant Human Insulin Deposited 2019-02-18 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；298 K；PEG 6000 30%
Resolution 1.58 Å R-free 0.201
6P4Z Structure of gadolinium-caged cobalt (III) insulin hexamer Deposited 2019-05-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded CO COBALT (II) ION × 6 GD GADOLINIUM ATOM × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；18% (w/v) PEG 12,000 and 0.1 M HEPES pH 7.0
Resolution 1.80 Å R-free 0.239
6S34 Zinc free, dimeric human insulin determined to 1.35 Angstrom resolution Deposited 2019-06-24 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M Sodium Citrate, 0.1 M Sodium Hepes, pH 7.5, 20 % isopropanol
Resolution 1.35 Å R-free 0.177
6S4I Crystal structure of zinc free A14E, B25H, B29K(N(eps)-[2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl]), desB30 human insulin Deposited 2019-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：Y14E Mutation：F25H,des30 NO3 NITRATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；310 K；Protein solution: 25 mg/ml insulin added 0.1% (w/v) NVoy Precipitant: 6.0 M ammonium nitrate, 0.1 M Tris pH 8.5
Resolution 1.51 Å R-free 0.212
6S4J Crystal structure of zinc free A14E, B25H, B29K(N(eps)-[2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl]), desB27, desB30 human insulin Deposited 2019-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：Y14E Mutation：F25H,des27,des30 IMD IMIDAZOLE × 3 KUT KUT [2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl] × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.12M monosaccharides, 0.1M buffer system 1 pH 6.5, 20% (v/v) PEG500MME, 10% (w/v) Peg 20000 (F1 from Marpheus screen, Molecular Dimensions)
Resolution 1.50 Å R-free 0.210
6SOF human insulin receptor ectodomain bound by 4 insulin Deposited 2019-08-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE-PROPANE
Resolution 4.30 Å
6TC2 Monoclinic human insulin in complex with p-coumaric acid Deposited 2019-11-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 1–110（110 aa）
Chain B 1–110（110 aa）
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Chain E 1–110（110 aa）
Chain F 1–110（110 aa）
Chain G 1–110（110 aa）
Chain H 1–110（110 aa）
Chain I 1–110（110 aa）
Chain J 1–110（110 aa）
Chain K 1–110（110 aa）
Chain L 1–110（110 aa）
Not recorded ZN ZINC ION × 2 PO4 PHOSPHATE ION × 3 HC4 4'-HYDROXYCINNAMIC ACID × 5 SCN THIOCYANATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 5.82；298 K；12.78 mg/mL insulin, 0.77 mM zinc acetate, 40 mM p-coumaric acid, 3.2%(w/v) PEG-1000, 10 mM sodium thiocyanate, 0.4 M phosphate mixture (Na2HPO4, KH2PO4), pH = 5.82
Resolution 1.36 Å R-free 0.188
6TYH Four-Disulfide Insulin Analog A22/B22 Deposited 2019-08-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa） Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain B 25–54（30 aa）
Chain C 90–110（21 aa） Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain D 25–54（30 aa）
Chain E 90–110（21 aa） Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain F 25–54（30 aa）
Chain G 90–110（21 aa） Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain H 25–54（30 aa）
Chain I 90–110（21 aa） Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain J 25–54（30 aa）
Chain K 90–110（21 aa） Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain L 25–54（30 aa）
Mutation：R22C Mutation：R22C Mutation：R22C Mutation：R22C Mutation：R22C Mutation：R22C IPH PHENOL × 7 ACN ACETONE × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Citrate, Phenol, Acetone, Zinc acetate
Resolution 1.60 Å R-free 0.196
6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5 Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
Resolution 2.90 Å R-free 0.225
6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5 Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
Resolution 2.90 Å R-free 0.225
6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5 Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
Resolution 2.90 Å R-free 0.225
6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5 Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
Resolution 2.90 Å R-free 0.225
6VER Human insulin analog: [GluB10,TyrB20]-DOI Deposited 2020-01-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–46（22 aa）
Mutation：H10E, G20Y No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；300 K；Well condition: 100 mM Tri-HCl (pH 8.5) + 0.28 M magnesium formate. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
Resolution 1.05 Å R-free 0.205
6VES Human insulin analog: [GluB10,HisA8,ArgA9]-DOI Deposited 2020-01-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–46（22 aa）
Mutation：T8H, S9R Mutation：H10E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；300 K；WELL CONDITION: 0.2 M calcium acetate, 0.1 M imidazole (pH 8) + 10% w/v PEG 8000 Protein was provided as a sample comprising 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol of the analog
Resolution 1.85 Å R-free 0.239
6VET Human insulin analog: [GluB10,HisA8,ArgA9,TyrB20]-DOI Deposited 2020-01-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–46（22 aa）
Mutation：T8H, S9R Mutation：H10E,G20Y No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；300 K；Well condition: 0.3 M magnesium formate plus 0.1 M TrisHCl. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
Resolution 1.46 Å R-free 0.238
6VET Human insulin analog: [GluB10,HisA8,ArgA9,TyrB20]-DOI Deposited 2020-01-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–46（22 aa）
Mutation：T8H, S9R Mutation：H10E,G20Y No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；300 K；Well condition: 0.3 M magnesium formate plus 0.1 M TrisHCl. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
Resolution 1.46 Å R-free 0.238
6VET Human insulin analog: [GluB10,HisA8,ArgA9,TyrB20]-DOI Deposited 2020-01-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain E 90–110（21 aa）
Chain F 25–46（22 aa）
Mutation：T8H, S9R Mutation：H10E,G20Y No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；300 K；Well condition: 0.3 M magnesium formate plus 0.1 M TrisHCl. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
Resolution 1.46 Å R-free 0.238
6X4X B24Y DKP insulin Deposited 2020-05-24 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 7.4；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR measurement conditions pH 7.4；303 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR sample composition 0.5 mM 13C, 15N B24YDKP, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.5 mM B24DKP, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
Resolution 2.42 Å R-free 0.275
6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
Resolution 2.42 Å R-free 0.275
6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
Resolution 2.42 Å R-free 0.275
6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
Resolution 2.42 Å R-free 0.275
6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain M 90–110（21 aa）
Chain N 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
Resolution 2.42 Å R-free 0.275
6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 6 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
Resolution 2.42 Å R-free 0.275
6Z7Y Human insulin in complex with the analytical antibody OXI-005 Fab Deposited 2020-06-02 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M magnesium chloride, 0.1 M Tris, pH 8, 20 % (w/v) PEG 6000
Resolution 2.20 Å R-free 0.253
6Z7Y Human insulin in complex with the analytical antibody OXI-005 Fab Deposited 2020-06-02 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M magnesium chloride, 0.1 M Tris, pH 8, 20 % (w/v) PEG 6000
Resolution 2.20 Å R-free 0.253
7BW7 Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin. Deposited 2020-04-13 Different construct Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 3 PDB declaration: trimeric
Chain D 25–53（29 aa）
Chain D 90–110（21 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.10 Å
7BW8 Cryo-EM Structure for the Insulin Binding Region in the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin Deposited 2020-04-14 Different construct Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 3 PDB declaration: trimeric
Chain D 25–53（29 aa）
Chain D 90–110（21 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.80 Å
7BWA Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 2 Insulin Deposited 2020-04-14 Different construct Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric
Chain E 25–53（29 aa） Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
Chain E 90–110（21 aa） Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.90 Å
7BWA Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 2 Insulin Deposited 2020-04-14 Different construct Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 2 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric
Chain D 25–53（29 aa） Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
Chain D 90–110（21 aa） Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.90 Å
7JP3 Des-B29,B30-insulin Deposited 2020-08-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 25–52（28 aa）
Chain A 90–110（21 aa）
Chain B 25–52（28 aa）
Chain B 90–110（21 aa）
Chain C 25–52（28 aa）
Chain C 90–110（21 aa）
Chain D 25–52（28 aa）
Chain D 90–110（21 aa）
Chain E 25–52（28 aa）
Chain E 90–110（21 aa）
Chain F 25–52（28 aa）
Chain F 90–110（21 aa）
Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；1:2.5 ratio of Zn2+ to protein monomer in 0.02M Tris-HCl, 0.05M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, PH 8.0
Resolution 1.95 Å R-free 0.249
7MD4 Insulin receptor ectodomain dimer complexed with two IRPA-3 partial agonists Deposited 2021-04-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.50 Å
7MD5 Insulin receptor ectodomain dimer complexed with two IRPA-9 partial agonists Deposited 2021-04-03 Different construct Different mutation/modification Different oligomeric state Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 12 PDB declaration: dodecameric
Chain O 90–110（21 aa）
Chain P 25–54（30 aa）
Chain Q 90–110（21 aa）
Chain R 25–54（30 aa）
Chain S 90–110（21 aa）
Chain T 25–54（30 aa）
Chain U 90–110（21 aa）
Chain V 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 5.20 Å
7MQO The insulin receptor ectodomain in complex with a venom hybrid insulin analog - "head" region Deposited 2021-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–46（22 aa）
Chain C 90–110（21 aa）
Chain D 25–46（22 aa）
Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 12 ELECTRON MICROSCOPY
cryo-EM buffer pH 8；Equal parts HBS( 50 mM HEPES pH 7.5, 150 mM NaCl ) and TBS (25 mM Tris pH 8.5, 150 mM NaCl)
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
7MQR The insulin receptor ectodomain in complex with four venom hybrid insulins - symmetric conformation Deposited 2021-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain A 90–110（21 aa）
Chain B 25–46（22 aa）
Chain C 90–110（21 aa）
Chain D 25–46（22 aa）
Chain G 90–110（21 aa）
Chain H 25–46（22 aa）
Chain I 90–110（21 aa）
Chain J 25–46（22 aa）
Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 20 ELECTRON MICROSCOPY
cryo-EM buffer pH 8；Equal parts HBS(50 mM HEPES pH 7.5, 150 mM NaCl ) and TBS (25 mM Tris pH 8.5, 150 mM NaCl)
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.10 Å
7MQS The insulin receptor ectodomain in complex with three venom hybrid insulin molecules - asymmetric conformation Deposited 2021-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain A 90–110（21 aa）
Chain B 25–46（22 aa）
Chain C 90–110（21 aa）
Chain D 25–46（22 aa）
Chain G 90–110（21 aa）
Chain H 25–46（22 aa）
Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8；Equal parts HBS(50 mM HEPES pH 7.5, 150 mM NaCl ) and TBS (25 mM Tris pH 8.5, 150 mM NaCl)
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.40 Å
7NHU Crystal structure of desB30 insulin produced by cell free protein synthesis Deposited 2021-02-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：des30 No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M sodium formate, 20 % (w/v) PEG 3350
Resolution 1.40 Å R-free 0.171
7PG0 Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin with visible ddm micelle, conf 1 Deposited 2021-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE；Blotted for 3s prior to plunging
Resolution 7.60 Å
7PG2 Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin, conf 1 Deposited 2021-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE；Blotted for 3s prior to plunging
Resolution 6.70 Å
7PG3 Low resolution Cryo-EM structure of the full-length insulin receptor bound to 3 insulin, conf 2 Deposited 2021-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE；Blotted for 3s prior to plunging
Resolution 7.30 Å
7PG4 Low resolution Cryo-EM structure of the full-length insulin receptor bound to 2 insulin, conf 3 Deposited 2021-08-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE；Blotted for 3s prior to plunging
Resolution 9.10 Å
7QAC The T2 structure of polycrystalline cubic human insulin Deposited 2021-11-16 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule POWDER DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 8.56；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions BATCH MODE；pH 7.88；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions BATCH MODE；pH 8.02；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions BATCH MODE；pH 8.17；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions BATCH MODE；pH 8.26；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions BATCH MODE；pH 8.17；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
Resolution 2.29 Å
7QGF Cubic Insulin SAD phasing at 14.2 keV Deposited 2021-12-08 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain AAA 90–110（21 aa）
Chain BBB 25–53（29 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.4 M NAPO4/NA2HPO4 PH 10.4, 0.001 M EDTA,30%ETHYLENE GLYCOL
Resolution 1.20 Å R-free 0.165
7QID tentative model of the human insulin receptor ectodomain bound by three insulin Deposited 2021-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE-PROPANE
Resolution 5.00 Å
7RKD X-Ray structure of Insulin Analog GLULISINE Deposited 2021-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions MICROBATCH；293.15 K；0.1 M Magnesium formate dihydrate
Resolution 1.25 Å R-free 0.215
7RZE Insulin Degrading Enzyme pO/pC Deposited 2021-08-27 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain a 90–110（21 aa）
Chain b 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.30 Å
7RZF Insulin Degrading Enzyme O/pC Deposited 2021-08-27 Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain a 90–110（21 aa）
Chain b 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
7RZI Insulin Degrading Enzyme pC/pC Deposited 2021-08-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain a 90–110（21 aa）
Chain b 25–54（30 aa）
Chain c 90–110（21 aa）
Chain d 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.00 Å
7S4Y Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Insulin Deposited 2021-09-09 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded ZN ZINC ION × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；298 K；insulin was dissolved in 5 mM zinc chloride, 25 mM HCl at a concentration of 5-10 mg/ml. Cuboid-shaped microcrystals were obtained in 35.2 mM sodium citrate pH 7, and 5% (v/v) acetone as precipitant
Resolution 1.71 Å R-free 0.258
7S4Y Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Insulin Deposited 2021-09-09 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；298 K；insulin was dissolved in 5 mM zinc chloride, 25 mM HCl at a concentration of 5-10 mg/ml. Cuboid-shaped microcrystals were obtained in 35.2 mM sodium citrate pH 7, and 5% (v/v) acetone as precipitant
Resolution 1.71 Å R-free 0.258
7SL1 Full-length insulin receptor bound with site 1 binding deficient mutant insulin (A-V3E) Deposited 2021-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 25–54（30 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 90–110（21 aa）
Mutation：V3E Mutation：V3E No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
7SL2 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- asymmetric conformation Deposited 2021-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain C 25–54（30 aa）
Chain D 25–54（30 aa）
Chain E 25–54（30 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 90–110（21 aa）
Chain I 90–110（21 aa）
Chain J 90–110（21 aa）
Mutation：L13R Mutation：L13R Mutation：L13R Mutation：L13R No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.60 Å
7SL3 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- symmetric conformation Deposited 2021-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 25–54（30 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 90–110（21 aa）
Mutation：L13R Mutation：L13R No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
7SL4 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- asymmetric conformation Deposited 2021-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 25–54（30 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 90–110（21 aa）
Mutation：L17R Mutation：L17R No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 5.00 Å
7SL6 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- symmetric conformation Deposited 2021-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 90–110（21 aa）
Chain D 90–110（21 aa）
Chain E 25–54（30 aa）
Chain F 25–54（30 aa）
Mutation：L17R Mutation：L17R No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.70 Å
7SL7 Full-length insulin receptor bound with both site 1 binding deficient mutant insulin (A-V3E) and site 2 binding deficient mutant insulin (A-L13R) Deposited 2021-10-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain C 90–110（21 aa）
Chain D 90–110（21 aa）
Chain E 90–110（21 aa）
Chain F 90–110（21 aa）
Chain G 25–54（30 aa）
Chain H 25–54（30 aa）
Chain I 25–54（30 aa）
Chain J 25–54（30 aa）
Mutation：L13R Mutation：L13R Mutation：V3E Mutation：V3E No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
7STH Full-length insulin receptor bound with unsaturated insulin WT (2 insulin bound) symmetric conformation Deposited 2021-11-13 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.50 Å
7STI Full-length insulin receptor bound with unsaturated insulin WT (1 insulin bound) asymmetric conformation Deposited 2021-11-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.90 Å
7STJ Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 1) Deposited 2021-11-14 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.40 Å
7STK Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 2) Deposited 2021-11-14 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.00 Å
7U6E Head region of insulin receptor ectodomain (A-isoform) bound to the non-insulin agonist IM462 Deposited 2022-03-03 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa） Fragment：UNP residues 90-110
Chain B 25–54（30 aa） Fragment：UNP residues 25-54
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.00 Å
7YQ3 human insulin receptor bound with A43 DNA aptamer and insulin Deposited 2022-08-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: pentameric
Chain A 90–110（21 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.60 Å
7YQ4 human insulin receptor bound with A62 DNA aptamer and insulin - locally refined Deposited 2022-08-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: pentameric
Chain A 90–110（21 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.95 Å
7YQ5 human insulin receptor bound with A62 DNA aptamer and insulin Deposited 2022-08-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: pentameric
Chain A 90–110（21 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.27 Å
7Z5L Crystal structure of human insulin, crystallised in the presence of macrophage migration inhibitory factor (MIF) and dimethyl sulfoxide (DMSO) Deposited 2022-03-09 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1 M Tris pH 7.5, 1.25 M ammonium sulfate and 8% (v/v) 2-propanol
Resolution 1.40 Å R-free 0.171
7Z5Q Crystal structure of human insulin, crystallised in the presence of macrophage migration inhibitory factor (MIF) and p-Hydroxyphenylpyruvate (HPP) Deposited 2022-03-09 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1 M Tris pH 7.5, 1.25 M ammonium sulfate and 8% (v/v) 2-propanol
Resolution 1.80 Å R-free 0.183
8EYX Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Asymmetric conformation 1 Deposited 2022-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain D 1–110（110 aa）
Chain E 1–110（110 aa）
Chain F 1–110（110 aa）
Chain G 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.50 Å
8EYY Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S, denoted as IR-3CS) Asymmetric conformation 2 Deposited 2022-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Chain E 1–110（110 aa）
Chain F 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.90 Å
8EZ0 Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Symmetric conformation Deposited 2022-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain D 1–110（110 aa）
Chain E 1–110（110 aa）
Chain F 1–110（110 aa）
Chain G 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.70 Å
8GSG T3R3 form of Human insulin with single Zn Deposited 2022-09-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded CRS M-CRESOL × 6 NA SODIUM ION × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；0.1 M HEPES pH7.5,10% (v/v) PEG 6000, 5% (v/v) MPD
Resolution 2.05 Å R-free 0.205
8GUY human insulin receptor bound with two insulin molecules Deposited 2022-09-14 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain C 90–110（21 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.18 Å
8HGZ Crystal structure of insulin Deposited 2022-11-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain I 90–110（21 aa）
Chain J 25–53（29 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 1.70 Å R-free 0.258
8HGZ Crystal structure of insulin Deposited 2022-11-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain M 90–110（21 aa）
Chain N 25–53（29 aa）
Not recorded IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 1.70 Å R-free 0.258
8HSF Insulin triple mutant INS-RQD Deposited 2022-12-19 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Mutation：S9R,H10Q,E13D No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；1M Imidazole
Resolution 2.90 Å R-free 0.283
8HSF Insulin triple mutant INS-RQD Deposited 2022-12-19 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Mutation：S9R,H10Q,E13D No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；1M Imidazole
Resolution 2.90 Å R-free 0.283
8HSK Insulin single mutant INS-Q Deposited 2022-12-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Mutation：H10Q SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.2M Ammonium sulphate, 0.1M MES monohydrate, 30% w/v PEG MME
Resolution 1.64 Å R-free 0.165
8IPZ Crystal structure of insulin detemir Deposited 2023-03-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M TRIS hydrochloride
Resolution 1.40 Å R-free 0.230
8IPZ Crystal structure of insulin detemir Deposited 2023-03-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M TRIS hydrochloride
Resolution 1.40 Å R-free 0.230
8OKY Crystal structure of D-ProB26-DTriA analogue of human insulin Deposited 2023-03-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–51（27 aa）
Mutation：D-ProB26 Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.2；293 K；0.3 M Tris/HCl pH 8.2, 0.6 M Na2SO4, 0.6 mM ZnAc
Resolution 1.17 Å R-free 0.166
8ONI Human insulin in complex with the analytical antibody S1 Fab Deposited 2023-04-03 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain B 25–54（30 aa）
Chain I 90–110（21 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M HEPES pH 7.5, 25%(w/v) PEG 2000 MME
Resolution 2.30 Å R-free 0.237
8ONI Human insulin in complex with the analytical antibody S1 Fab Deposited 2023-04-03 Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain F 25–54（30 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M HEPES pH 7.5, 25%(w/v) PEG 2000 MME
Resolution 2.30 Å R-free 0.237
8ONK Human insulin in complex with the analytical antibody S1 Fab and the analytical antibody HUI-001 Fab Deposited 2023-04-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain B 25–54（30 aa）
Chain I 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M TRIS pH 7.5, 15%(w/v) PEG 6000
Resolution 3.40 Å R-free 0.311
8ONK Human insulin in complex with the analytical antibody S1 Fab and the analytical antibody HUI-001 Fab Deposited 2023-04-03 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 25–54（30 aa）
Chain D 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M TRIS pH 7.5, 15%(w/v) PEG 6000
Resolution 3.40 Å R-free 0.311
8ONP Human insulin trans-HypB26-DTIA analogue Deposited 2023-04-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4；293 K；0.1 M Na2SO4
Resolution 1.77 Å R-free 0.271
8ONR Crystal structure of human insulin trans-HypB26-DTI analogue Deposited 2023-04-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–50（26 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 2 IPH PHENOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.2；292 K；0.3M Na2SO4 0.3M Tris pH 8.2 0.6mM ZnAc 0.06% Phenol
Resolution 1.88 Å R-free 0.312
8PI4 Crystal structure of human insulin desB30 precursor with an Alanine-Methionine-Lysine C-peptide in dimer (T2) conformation Deposited 2023-06-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 25–53（29 aa）
Chain A 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；0.2 M sodium acetate trihydrate, 0.1 M Tris, pH 8.5, 30 % (w/v) PEG 4000
Resolution 1.25 Å R-free 0.175
8PI5 Crystal structure of human insulin desB30 precursor with an Alanine-Methionine-Lysine C-peptide in hexamer (T3R3) conformation Deposited 2023-06-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: dimeric
Chain B 25–53（29 aa）
Chain B 90–110（21 aa）
Chain D 25–53（29 aa）
Chain D 90–110（21 aa）
Not recorded ZN ZINC ION × 12 CL CHLORIDE ION × 3 RCO RESORCINOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 9；291 K；6 mg/ml protein, 20 mM resorcinol, 0.5 Zn2+ (from zinc acetate) per insuln monomer in water, pH 7.95 precipitant: 0.1 M Bicine, pH 9.0, 2 % (v/v) 1,4-dioxane, 10 % (w/v) PEG 20000
Resolution 1.66 Å R-free 0.179
8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 25–53（29 aa）
Chain A 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
Resolution 2.14 Å R-free 0.288
8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 25–53（29 aa）
Chain B 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
Resolution 2.14 Å R-free 0.288
8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain C 25–53（29 aa）
Chain C 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
Resolution 2.14 Å R-free 0.288
8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain D 25–53（29 aa）
Chain D 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
Resolution 2.14 Å R-free 0.288
8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain E 25–53（29 aa）
Chain E 90–110（21 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
Resolution 2.14 Å R-free 0.288
8RRP Insulin Icodec - A14E B16H B25H B29Ne-C20 diacid-LgGlu-2xAdo desB30 human insulin Deposited 2024-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Mutation：Y14E Mutation：Y14E Mutation：Y14E ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；0.02 calcium chloride 30 % 2-methyl-2,4-pentanediol 0.1M acetate pH4.6
Resolution 2.00 Å R-free 0.217
8RVT Structure of full-length human insulin fibrils Deposited 2024-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 10 PDB declaration: decameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Not recorded No recorded non-water small molecule SOLID-STATE NMR
NMR measurement conditions pH 1.9；298 K；Ionic strength (raw mmCIF value) 0.01；Pressure 1
NMR sample composition 10 mg/L [U-100% 13C; U-100% 15N] Insulin chain A, 10 mg/mL [U-100% 13C; U-100% 15N] Insulin chain B, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
8SBD Cryo-EM structure of insulin amyloid-like fibril that is composed of two antiparallel protofilaments Deposited 2023-04-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 32 PDB declaration: 32-meric
Chain A 90–110（21 aa）
Chain B 90–110（21 aa）
Chain C 90–110（21 aa）
Chain D 90–110（21 aa）
Chain E 90–110（21 aa）
Chain F 90–110（21 aa）
Chain G 90–110（21 aa）
Chain H 90–110（21 aa）
Chain I 90–110（21 aa）
Chain J 90–110（21 aa）
Chain K 90–110（21 aa）
Chain L 90–110（21 aa）
Chain M 90–110（21 aa）
Chain N 90–110（21 aa）
Chain O 90–110（21 aa）
Chain P 90–110（21 aa）
Chain a 25–54（30 aa）
Chain b 25–54（30 aa）
Chain c 25–54（30 aa）
Chain d 25–54（30 aa）
Chain e 25–54（30 aa）
Chain f 25–54（30 aa）
Chain g 25–54（30 aa）
Chain h 25–54（30 aa）
Chain i 25–54（30 aa）
Chain j 25–54（30 aa）
Chain k 25–54（30 aa）
Chain l 25–54（30 aa）
Chain m 25–54（30 aa）
Chain n 25–54（30 aa）
Chain o 25–54（30 aa）
Chain p 25–54（30 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 2
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.20 Å
8VCX Human TCR A2.13 in complex with DQ8-InsCpep Deposited 2023-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric
Chain C 64–78（15 aa）
Mutation：G9E, L11C PO4 PHOSPHATE ION × 1 GOL GLYCEROL × 5 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293.15 K；0.2 M Potassium sodium tartrate, 24% PEG 3350
Resolution 2.59 Å R-free 0.238
8VDD Crystal structure of Proinsulin C-peptide bound to HLA-DQ8 Deposited 2023-12-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain C 64–78（15 aa）
Mutation：G9E, L11C NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；293.15 K；0.2 M K Na tartrate, 14% w/v PEG 20,000 with seeding and additive C8 silver bullet
Resolution 2.60 Å R-free 0.280
8WU0 Crystal structure of lisargine Deposited 2023-10-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–109（20 aa）
Chain B 25–56（32 aa）
Chain C 90–109（20 aa）
Chain D 25–56（32 aa）
Not recorded ZN ZINC ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 7.5；283 K；24% (v/v) 2-Propanol, 0.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES sodium pH 7.5
Resolution 1.95 Å R-free 0.214
8YYS Cryo-EM structure of the complex IR with two insulin Deposited 2024-04-04 Different construct Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.14 Å
8Z4B Crystal structure of LysB22-AspB28 insulin analog at ambient structure Deposited 2024-04-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: 12-meric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZN ZINC ION × 6 CL CHLORIDE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；2.4 M NaCl, 100 mM Tris-HCl at pH 7.4, 6 mM ZnCI2, 20 (w/v) poly(ethylene glycol) PEG-8000
Resolution 2.50 Å R-free 0.357
9CIV X-Ray Structure of Insulin Analog DETEMIR Deposited 2024-07-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 3 ZN ZINC ION × 6 CL CHLORIDE ION × 6 CRS M-CRESOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions MICROBATCH；293 K；0.2M Lithium sulfate monohydrate, 0.1M Tris pH 8.5, 25% w/v PEG 3350
Resolution 1.60 Å R-free 0.248
9DNN Insulin receptor in complex with both insulin and de novo designed site-2 binder "S2B". Deposited 2024-09-17 Different construct Different oligomeric state Different ligand/ion Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain C 1–110（110 aa）
Chain D 1–110（110 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 6.10 Å
9IBB Rhombohedral crystalline form of human insulin complexed with m-cresol Deposited 2025-02-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded CRS M-CRESOL × 2 SCN THIOCYANATE ION × 1 ZN ZINC ION × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 7.5；294.15 K；13.14 mg/mL human insulin, 0.80 mM zinc acetate, 0.51% v/v m-cresol in ethanol, 10.25 mM sodium thiocyanate, 0.4 M sodium-monopotassium phosphate mixture
Resolution 1.84 Å R-free 0.224
9LVC Temperature induces a shift from the dihexamer to the hexamer form of insulin Deposited 2025-02-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 2.30 Å R-free 0.287
9LVC Temperature induces a shift from the dihexamer to the hexamer form of insulin Deposited 2025-02-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 2.30 Å R-free 0.287
9LVD Temperature induces a shift from the dihexamer to the hexamer form of insulin (200K) Deposited 2025-02-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 2.85 Å R-free 0.330
9LVE Temperature induces a shift from the dihexamer to the hexamer form of insulin (300K) Deposited 2025-02-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 2.88 Å R-free 0.388
9LVX di-hexamer form of insulin detemir at ambient temperature Deposited 2025-02-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 2.70 Å R-free 0.322
9LVX di-hexamer form of insulin detemir at ambient temperature Deposited 2025-02-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 2.70 Å R-free 0.322
9LVY hexamer form of insulin detemir at ambient temperature Deposited 2025-02-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
Resolution 2.85 Å R-free 0.338
9M4X Cubic insulin crystal, Esrapid, at pH 2 Deposited 2025-03-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 2
Resolution 1.40 Å R-free 0.221
9M4Y Cubic insulin crystal, Esrapid, at pH 3 Deposited 2025-03-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 3
Resolution 1.40 Å R-free 0.214
9M4Z Cubic insulin crystal, Esrapid, at pH 4 Deposited 2025-03-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 4
Resolution 1.50 Å R-free 0.217
9M50 Cubic insulin crystal, Esrapid, at pH 5 Deposited 2025-03-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 5
Resolution 1.40 Å R-free 0.211
9M51 Cubic insulin crystal, Esrapid, at pH 6 Deposited 2025-03-05 Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–109（20 aa）
Chain B 25–53（29 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 6
Resolution 1.76 Å R-free 0.226
9PUW Insulin Receptor bound to Ins-AC-S2 Deposited 2025-07-31 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric
Chain P 25–53（29 aa）
Chain R 25–53（29 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY mmCIF provides none of the parsed conditions Resolution 3.64 Å
9PVO Novel site 1 interaction of the IR/Ins-AC-S2 complex Deposited 2025-08-03 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric
Chain R 25–53（29 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY mmCIF provides none of the parsed conditions Resolution 3.89 Å
9QLD Rhombohedral crystalline form of human insulin complexed with m-nitrophenol Deposited 2025-03-20 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded ZCQ 3-nitrophenol × 1 SCN THIOCYANATE ION × 1 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 7.5；294.15 K；12.78 mg/mL human insulin, 0.77 mM zinc acetate, 40.06 mM m-nitrophenol, 10.09 mM sodium thiocyanate, 0.4 M sodium-monopotassium phosphate mixture
Resolution 2.55 Å R-free 0.240
9QLD Rhombohedral crystalline form of human insulin complexed with m-nitrophenol Deposited 2025-03-20 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Not recorded ZCQ 3-nitrophenol × 1 ZN ZINC ION × 1 ACT ACETATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 7.5；294.15 K；12.78 mg/mL human insulin, 0.77 mM zinc acetate, 40.06 mM m-nitrophenol, 10.09 mM sodium thiocyanate, 0.4 M sodium-monopotassium phosphate mixture
Resolution 2.55 Å R-free 0.240
9R48 Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 9.0 (apo state) Deposited 2025-05-07 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0
Resolution 1.65 Å R-free 0.196
9R49 Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (25 ms soaking) Deposited 2025-05-07 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 25 ms
Resolution 1.64 Å R-free 0.198
9R4A Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (50 ms soaking) Deposited 2025-05-07 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 50 ms
Resolution 1.45 Å R-free 0.196
9R4B Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (250 ms soaking) Deposited 2025-05-07 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 250 ms
Resolution 1.50 Å R-free 0.208
9R4C Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (500 ms soaking) Deposited 2025-05-07 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 500 ms
Resolution 1.41 Å R-free 0.201
9R4E Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (5 s soaking) Deposited 2025-05-07 Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Not recorded SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 5 s
Resolution 1.30 Å R-free 0.194
9UTJ Monoclinic crystal structure of acid-stable protracted insulin Deposited 2025-05-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–53（29 aa）
Chain C 90–110（21 aa）
Chain D 25–53（29 aa）
Chain E 90–110（21 aa）
Chain F 25–53（29 aa）
Chain G 90–110（21 aa）
Chain H 25–53（29 aa）
Chain I 90–110（21 aa）
Chain J 25–53（29 aa）
Chain K 90–110（21 aa）
Chain L 25–53（29 aa）
Not recorded CRS M-CRESOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 CA CALCIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；200mM CaCl2 buffered in 100mM Tris-HCl pH 8,5, 30% (v/v) 2-Methyl-2,4-pentanediol, 8% (w/v) PEG 8000
Resolution 1.95 Å R-free 0.235
9UTK Monoclinic crystal structure of acid-stable protracted insulin (293 K) Deposited 2025-05-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric
Chain A 90–110（21 aa）
Chain B 25–54（30 aa）
Chain C 90–110（21 aa）
Chain D 25–54（30 aa）
Chain E 90–110（21 aa）
Chain F 25–54（30 aa）
Chain G 90–110（21 aa）
Chain H 25–54（30 aa）
Chain I 90–110（21 aa）
Chain J 25–54（30 aa）
Chain K 90–110（21 aa）
Chain L 25–54（30 aa）
Not recorded IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 CA CALCIUM ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；200mM CaCl2 buffered in 100mM Tris-HCl pH 8,5, 30% (v/v) 2-Methyl-2,4-pentanediol, 8% (w/v) PEG 8000
Resolution 2.38 Å R-free 0.302

369 other PDB entries and 583 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name INS_HUMAN
Isoform —
PDB entities 2, 3
Chains and sequence ranges Author chain E； PDBConstruct 1–21； UniProt 90–110 Author chain F； PDBConstruct 1–30； UniProt 25–54

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 7v3p

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 7v3p
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id7v3p
Deposition date deposition_date2021-08-11
Structure title titleCryo-EM structure of the IGF1R/insulin complex
Keywords keywordsThe type 1 insulin-like growth factor receptor (IGF1R), MEMBRANE PROTEIN; MEMBRANE PROTEIN
Experimental Method methodELECTRON MICROSCOPY
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier49.58 Å
Radius of gyration Rg (electron density) rg_electron49.54 Å
Forward intensity I(0) i0558186000.00
Molecular weight molecular_weight192480.0 kDa
Excluded volume excluded_volume239670 ų
Envelope volume envelope_volume379070 ų
Hydration-shell volume shell_volume66237 ų
Envelope diameter envelope_diameter181.2 Å
Shell Rg shell_rg51.70 Å
Envelope Rg envelope_rg47.57 Å
Shape Rg shape_rg49.54 Å
Total Rg total_rg49.64 Å
Total atoms total_atoms26387
Residues n_residues1674
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax170.0 Å
Rg (real space) rg_real49.80 Å
Rg uncertainty (real space) rg_real_error2.04 Å
I(0) (real space) i0_real5.5820e+08
I(0) uncertainty (real space) i0_real_error1.0770e+07
Rg (reciprocal space) rg_reciprocal49.59 Å
I(0) (reciprocal space) i0_reciprocal558000000.0000
Solution quality estimate total_estimate0.8755
Solution quality rating solution_quality GOOD a GOOD solution
P(r) peaks n_peaks2
Primary peak position r_peak_primary53.1 Å
Skewness Skewness skewness0.355
Kurtosis Kurtosis kurtosis-0.525
Angular range angular_range— – 0.1600 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha37690000.0000
Real-space data points n_real_points33
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.863; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.959; Smooth: 0.831
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (4)

▼

7. Fold Classification (SCOP + CATH) 2 domains

CATH v4.4 (2 domains)

Domain ID domain_id7v3pB01
Class class3 — Alpha Beta
Architecture architecture80 — Alpha-Beta Horseshoe
Topology topology20 — 24 nucleotide stem-loop, u2 snrnp hairpin iv. U2 a'; Chain A
Homologous superfamily homologous superfamily20 — Receptor L-domain
Domain ID domain_id7v3pB02
Class class2 — Mainly Beta
Architecture architecture10 — Ribbon
Topology topology220 — Hormone Receptor, Insulin-like Growth Factor Receptor 1; Chain A domain 2
Homologous superfamily homologous superfamily10 — Hormone Receptor, Insulin-like Growth Factor Receptor 1; Chain A, domain 2
▶

8. Citations (1)

▶

9. Files and Curves (10)